WO2006028284A1 - モルホリン化合物 - Google Patents
モルホリン化合物 Download PDFInfo
- Publication number
- WO2006028284A1 WO2006028284A1 PCT/JP2005/017002 JP2005017002W WO2006028284A1 WO 2006028284 A1 WO2006028284 A1 WO 2006028284A1 JP 2005017002 W JP2005017002 W JP 2005017002W WO 2006028284 A1 WO2006028284 A1 WO 2006028284A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituent
- methyl
- morpholine
- acetamide
- ylthio
- Prior art date
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title claims description 347
- -1 Morpholine compound Chemical class 0.000 title claims description 336
- 150000001875 compounds Chemical class 0.000 claims abstract description 363
- 150000003839 salts Chemical class 0.000 claims abstract description 71
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 60
- 239000012453 solvate Substances 0.000 claims abstract description 47
- 125000000732 arylene group Chemical group 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 474
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 428
- 125000001424 substituent group Chemical group 0.000 claims description 296
- 238000000034 method Methods 0.000 claims description 251
- OEEFIWRHPLVZMX-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl]morpholine Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CCOCC1 OEEFIWRHPLVZMX-UHFFFAOYSA-N 0.000 claims description 123
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 56
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 56
- 125000002947 alkylene group Chemical group 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 125000003545 alkoxy group Chemical group 0.000 claims description 44
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 26
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 125000004434 sulfur atom Chemical group 0.000 claims description 24
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 18
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 14
- 208000010668 atopic eczema Diseases 0.000 claims description 13
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 12
- 230000000172 allergic effect Effects 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
- 201000009890 sinusitis Diseases 0.000 claims description 11
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 9
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 208000003926 Myelitis Diseases 0.000 claims description 9
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 9
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 9
- 201000010105 allergic rhinitis Diseases 0.000 claims description 9
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 claims description 8
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 8
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 8
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 7
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 4
- WORHOHAZPZLXKG-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]morpholine Chemical compound C1=C(F)C(F)=CC=C1CN1CCOCC1 WORHOHAZPZLXKG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004419 alkynylene group Chemical group 0.000 claims description 4
- MWAGASVCVQLNKO-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1COC(CNC(=O)C)CN1CC1=CC=C(Cl)C(Cl)=C1 MWAGASVCVQLNKO-UHFFFAOYSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 3
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims description 3
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 2
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 claims description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 538
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract description 7
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract description 7
- 208000026278 immune system disease Diseases 0.000 abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 abstract description 5
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 description 378
- 230000015572 biosynthetic process Effects 0.000 description 372
- 239000000047 product Substances 0.000 description 326
- 239000007787 solid Substances 0.000 description 236
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 129
- 238000005160 1H NMR spectroscopy Methods 0.000 description 126
- 238000005481 NMR spectroscopy Methods 0.000 description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 94
- 239000002904 solvent Substances 0.000 description 88
- 239000000203 mixture Substances 0.000 description 75
- 239000012230 colorless oil Substances 0.000 description 61
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- 239000002253 acid Substances 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 52
- 239000000243 solution Substances 0.000 description 52
- 230000002829 reductive effect Effects 0.000 description 49
- 239000012046 mixed solvent Substances 0.000 description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000003921 oil Substances 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 239000013078 crystal Substances 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 30
- 239000003480 eluent Substances 0.000 description 29
- 235000019270 ammonium chloride Nutrition 0.000 description 28
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 28
- 239000000843 powder Substances 0.000 description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 238000010992 reflux Methods 0.000 description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 125000004043 oxo group Chemical group O=* 0.000 description 15
- 210000003979 eosinophil Anatomy 0.000 description 14
- 229910052801 chlorine Inorganic materials 0.000 description 13
- QGJAVGUBPSOFKS-UHFFFAOYSA-N morpholine;dihydrochloride Chemical compound Cl.Cl.C1COCCN1 QGJAVGUBPSOFKS-UHFFFAOYSA-N 0.000 description 13
- OJBBVTPPCDAKPT-XRIOVQLTSA-N [(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1CO[C@@H](CN)CN1CC1=CC=C(Cl)C(Cl)=C1 OJBBVTPPCDAKPT-XRIOVQLTSA-N 0.000 description 12
- 229940126214 compound 3 Drugs 0.000 description 12
- 229940125898 compound 5 Drugs 0.000 description 12
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 125000000335 thiazolyl group Chemical group 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 102000019034 Chemokines Human genes 0.000 description 10
- 108010012236 Chemokines Proteins 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 125000002541 furyl group Chemical group 0.000 description 10
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 9
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 9
- 108050000299 Chemokine receptor Proteins 0.000 description 9
- 102000009410 Chemokine receptor Human genes 0.000 description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- OCVLSHAVSIYKLI-UHFFFAOYSA-N 3h-1,3-thiazole-2-thione Chemical compound SC1=NC=CS1 OCVLSHAVSIYKLI-UHFFFAOYSA-N 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- YNNGZCVDIREDDK-UHFFFAOYSA-N aminocarbamodithioic acid Chemical compound NNC(S)=S YNNGZCVDIREDDK-UHFFFAOYSA-N 0.000 description 8
- 229940125904 compound 1 Drugs 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 125000002098 pyridazinyl group Chemical group 0.000 description 7
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 125000000984 3-chloro-4-fluorobenzyl group Chemical group [H]C1=C(F)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 5
- ZEFGUWRQFNTGGX-UHFFFAOYSA-N 1,6-dihydropyridazine Chemical compound C1NN=CC=C1 ZEFGUWRQFNTGGX-UHFFFAOYSA-N 0.000 description 5
- CDBLCTFHNBQXJS-UHFFFAOYSA-N 4-[(3-fluorophenyl)methyl]morpholine Chemical compound FC1=CC=CC(CN2CCOCC2)=C1 CDBLCTFHNBQXJS-UHFFFAOYSA-N 0.000 description 5
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical class C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- UANWWXRZQGYWSR-JTQLQIEISA-N [(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methanamine Chemical compound C1CO[C@@H](CN)CN1CC1=CC=C(Cl)C(Cl)=C1 UANWWXRZQGYWSR-JTQLQIEISA-N 0.000 description 5
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 5
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 5
- 229940125758 compound 15 Drugs 0.000 description 5
- 229940125961 compound 24 Drugs 0.000 description 5
- 239000012990 dithiocarbamate Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 5
- 150000003512 tertiary amines Chemical class 0.000 description 5
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 4
- BTUOBEOTBYTRHO-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-phenylethane-1,2-dione Chemical compound ClC=1C=C(C=CC=1Cl)C(C(=O)C1=CC=CC=C1)=O BTUOBEOTBYTRHO-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- RLYUNPNLXMSXAX-UHFFFAOYSA-N 5-methylthiazole Chemical compound CC1=CN=CS1 RLYUNPNLXMSXAX-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 4
- 125000002785 azepinyl group Chemical group 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 229940047583 cetamide Drugs 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 3
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 3
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 3
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 3
- MXDRPNGTQDRKQM-UHFFFAOYSA-N 3-methylpyridazine Chemical compound CC1=CC=CN=N1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 description 3
- ZQKJCUYCOJCSDN-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl]morpholine dihydrochloride Chemical compound C1COCCN1CC2=CC(=C(C=C2)Cl)Cl.Cl.Cl ZQKJCUYCOJCSDN-UHFFFAOYSA-N 0.000 description 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 3
- ZAZICOWENJTYMB-UHFFFAOYSA-N 4-cyclopentylsulfonylbutanoic acid Chemical compound OC(=O)CCCS(=O)(=O)C1CCCC1 ZAZICOWENJTYMB-UHFFFAOYSA-N 0.000 description 3
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 3
- 108050005711 C Chemokine Proteins 0.000 description 3
- 102000017483 C chemokine Human genes 0.000 description 3
- 102000001902 CC Chemokines Human genes 0.000 description 3
- 108010040471 CC Chemokines Proteins 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000005835 indanylene group Chemical group 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000004957 naphthylene group Chemical group 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000005557 thiazolylene group Chemical group 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 2
- 125000005952 1,2,4-oxadiazolinyl group Chemical group 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 2
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 description 2
- UIFKCTYIXXQQGQ-UHFFFAOYSA-N 2-(6-oxo-1h-pyridazin-3-yl)ethanethioic s-acid Chemical compound OC(=S)CC=1C=CC(=O)NN=1 UIFKCTYIXXQQGQ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
- DYAQXLDQUHCRBU-UHFFFAOYSA-N 2-chloroacetamide;hydrochloride Chemical compound Cl.NC(=O)CCl DYAQXLDQUHCRBU-UHFFFAOYSA-N 0.000 description 2
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- IBWYHNOFSKJKKY-UHFFFAOYSA-N 3-chloropyridazine Chemical compound ClC1=CC=CN=N1 IBWYHNOFSKJKKY-UHFFFAOYSA-N 0.000 description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RSFDFESMVAIVKO-UHFFFAOYSA-N 3-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=CC(S)=C1 RSFDFESMVAIVKO-UHFFFAOYSA-N 0.000 description 2
- QSLDIPUHQBHQGY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine Chemical compound C1NCCC2=C1SC=N2 QSLDIPUHQBHQGY-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BKDUWMJFLCNPKP-UHFFFAOYSA-N 4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC=N1 BKDUWMJFLCNPKP-UHFFFAOYSA-N 0.000 description 2
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 2
- UMOUJDYMYCEROQ-UHFFFAOYSA-N 4-[(2,3-dichlorophenyl)methyl]morpholine Chemical compound ClC1=CC=CC(CN2CCOCC2)=C1Cl UMOUJDYMYCEROQ-UHFFFAOYSA-N 0.000 description 2
- NWMZWMSJQLEJTG-UHFFFAOYSA-N 4-[(3-chlorophenyl)methyl]morpholine Chemical compound ClC1=CC=CC(CN2CCOCC2)=C1 NWMZWMSJQLEJTG-UHFFFAOYSA-N 0.000 description 2
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 2
- ALDOZKXIKPFFOY-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]morpholine Chemical compound C1=CC(F)=CC=C1CN1CCOCC1 ALDOZKXIKPFFOY-UHFFFAOYSA-N 0.000 description 2
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 2
- PENVYHXKYYCYML-UHFFFAOYSA-N 4-methoxypyrimidine Chemical compound COC1=CC=NC=N1 PENVYHXKYYCYML-UHFFFAOYSA-N 0.000 description 2
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- GDGIVSREGUOIJZ-UHFFFAOYSA-N 5-amino-3h-1,3,4-thiadiazole-2-thione Chemical compound NC1=NN=C(S)S1 GDGIVSREGUOIJZ-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- NGKUQCFJZGLWIZ-UHFFFAOYSA-N ClC(CC1=CC=CC=C1)(C(CC1=CC=CC=C1)OCC1)N1Cl Chemical compound ClC(CC1=CC=CC=C1)(C(CC1=CC=CC=C1)OCC1)N1Cl NGKUQCFJZGLWIZ-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VONGZNXBKCOUHB-UHFFFAOYSA-N Phenylmethyl butanoate Chemical compound CCCC(=O)OCC1=CC=CC=C1 VONGZNXBKCOUHB-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- UNUBFMNTYGHURT-XRIOVQLTSA-N [(2s)-4-[(3-chloro-4-fluorophenyl)methyl]morpholin-2-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1CO[C@@H](CN)CN1CC1=CC=C(F)C(Cl)=C1 UNUBFMNTYGHURT-XRIOVQLTSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- OJBBVTPPCDAKPT-UHFFFAOYSA-N [4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1COC(CN)CN1CC1=CC=C(Cl)C(Cl)=C1 OJBBVTPPCDAKPT-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 125000004976 cyclobutylene group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004956 cyclohexylene group Chemical group 0.000 description 2
- 125000004979 cyclopentylene group Chemical group 0.000 description 2
- 125000004980 cyclopropylene group Chemical group 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000006286 dichlorobenzyl group Chemical group 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- BHIWKHZACMWKOJ-UHFFFAOYSA-N methyl isobutyrate Chemical compound COC(=O)C(C)C BHIWKHZACMWKOJ-UHFFFAOYSA-N 0.000 description 2
- XMVNUAHPLDBEJH-UHFFFAOYSA-N methyl pyrimidine-5-carboxylate Chemical compound COC(=O)C1=CN=CN=C1 XMVNUAHPLDBEJH-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 150000002780 morpholines Chemical class 0.000 description 2
- UUIQMZJEGPQKFD-UHFFFAOYSA-N n-butyric acid methyl ester Natural products CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 2
- 230000006824 pyrimidine synthesis Effects 0.000 description 2
- HBCQSNAFLVXVAY-UHFFFAOYSA-N pyrimidine-2-thiol Chemical compound SC1=NC=CC=N1 HBCQSNAFLVXVAY-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- JDDPITNKUXPLSB-UHFFFAOYSA-N tert-butyl morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1 JDDPITNKUXPLSB-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- VURWDDZIWBGXCK-DKWTVANSSA-N (2s)-2-amino-3-hydroxypropanamide;hydrochloride Chemical compound Cl.OC[C@H](N)C(N)=O VURWDDZIWBGXCK-DKWTVANSSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- XUPPFPAAYGASPH-UHFFFAOYSA-N (3-cyanophenoxy)boronic acid Chemical compound OB(O)OC1=CC=CC(C#N)=C1 XUPPFPAAYGASPH-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- PLFFHJWXOGYWPR-HEDMGYOXSA-N (4r)-4-[(3r,3as,5ar,5br,7as,11as,11br,13ar,13bs)-5a,5b,8,8,11a,13b-hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysen-3-yl]pentan-1-ol Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1[C@@H](CCCO)C PLFFHJWXOGYWPR-HEDMGYOXSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- 125000004814 1,1-dimethylethylene group Chemical group [H]C([H])([H])C([*:1])(C([H])([H])[H])C([H])([H])[*:2] 0.000 description 1
- 125000005970 1,2,4-thiadiazolinyl group Chemical group 0.000 description 1
- KGXLVHNMIAISQB-UHFFFAOYSA-N 1,2-dimethyl-2h-pyrimidine Chemical compound CC1N=CC=CN1C KGXLVHNMIAISQB-UHFFFAOYSA-N 0.000 description 1
- 125000005953 1,3,4-oxadiazolinyl group Chemical group 0.000 description 1
- QUKGLNCXGVWCJX-UHFFFAOYSA-N 1,3,4-thiadiazol-2-amine Chemical compound NC1=NN=CS1 QUKGLNCXGVWCJX-UHFFFAOYSA-N 0.000 description 1
- 125000005971 1,3,4-thiadiazolinyl group Chemical group 0.000 description 1
- WQVOUANKVCYEIQ-UHFFFAOYSA-N 1,3-thiazol-4-ylmethanol Chemical compound OCC1=CSC=N1 WQVOUANKVCYEIQ-UHFFFAOYSA-N 0.000 description 1
- IHDKBHLTKNUCCW-UHFFFAOYSA-N 1,3-thiazole 1-oxide Chemical compound O=S1C=CN=C1 IHDKBHLTKNUCCW-UHFFFAOYSA-N 0.000 description 1
- OPJYIWMGTSMLKB-UHFFFAOYSA-N 1,3-thiazole-2-carbohydrazide Chemical compound NNC(=O)C1=NC=CS1 OPJYIWMGTSMLKB-UHFFFAOYSA-N 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 1
- NNJJJHPWJUODKE-UHFFFAOYSA-N 1,6-dimethoxy-2h-pyrimidine Chemical compound CON1CN=CC=C1OC NNJJJHPWJUODKE-UHFFFAOYSA-N 0.000 description 1
- LZRHMQWWTSDSFV-UHFFFAOYSA-N 1,7-dimethoxy-2H-quinazoline Chemical compound CON1CN=CC2=CC=C(C=C12)OC LZRHMQWWTSDSFV-UHFFFAOYSA-N 0.000 description 1
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- HFKGAYOYTLGSQG-UHFFFAOYSA-N 1-hydroxy-2h-quinolin-2-ol Chemical compound C1=CC=C2N(O)C(O)C=CC2=C1 HFKGAYOYTLGSQG-UHFFFAOYSA-N 0.000 description 1
- PWGLCBCNZAZIIE-UHFFFAOYSA-N 1-methyl-2h-pyrimidine Chemical compound CN1CN=CC=C1 PWGLCBCNZAZIIE-UHFFFAOYSA-N 0.000 description 1
- XOHZHMUQBFJTNH-UHFFFAOYSA-N 1-methyl-2h-tetrazole-5-thione Chemical compound CN1N=NN=C1S XOHZHMUQBFJTNH-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BXYSFSIUKXZNSP-UHFFFAOYSA-N 1-phenylprop-1-en-2-amine Chemical group CC(N)=CC1=CC=CC=C1 BXYSFSIUKXZNSP-UHFFFAOYSA-N 0.000 description 1
- ZWAQJGHGPPDZSF-UHFFFAOYSA-N 1-prop-2-enylpiperazine Chemical class C=CCN1CCNCC1 ZWAQJGHGPPDZSF-UHFFFAOYSA-N 0.000 description 1
- 125000006411 1-propenylene group Chemical group [H]\C(*)=C(\[H])C([H])([H])[H] 0.000 description 1
- ZMCGLYQQWCHIOT-UHFFFAOYSA-N 1-sulfanylcyclohexa-2,4-diene-1-carboxylic acid Chemical compound OC(=O)C1(S)CC=CC=C1 ZMCGLYQQWCHIOT-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WITYIAHCBUYCSY-UHFFFAOYSA-N 1h-[1,3]thiazolo[5,4-b]pyridine-2-thione Chemical compound C1=CN=C2SC(S)=NC2=C1 WITYIAHCBUYCSY-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- YQQSRZSUGBETRS-UHFFFAOYSA-N 1h-pyridazine-6-thione Chemical compound SC1=CC=CN=N1 YQQSRZSUGBETRS-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- RYOLJRRNBRXUCN-UHFFFAOYSA-N 1h-pyrrole;hydrate Chemical compound O.C=1C=CNC=1 RYOLJRRNBRXUCN-UHFFFAOYSA-N 0.000 description 1
- UKLKVDKAWAOQAX-UHFFFAOYSA-N 2,2-bis[(2-methylpropan-2-yl)oxycarbonyl]propanedioic acid Chemical compound CC(C)(C)OC(=O)C(C(O)=O)(C(O)=O)C(=O)OC(C)(C)C UKLKVDKAWAOQAX-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- XYVIKUTYMMOQFT-UHFFFAOYSA-N 2,2-ditert-butylpropanedioic acid Chemical compound CC(C)(C)C(C(O)=O)(C(O)=O)C(C)(C)C XYVIKUTYMMOQFT-UHFFFAOYSA-N 0.000 description 1
- WSSWXGZEJNNFSN-UHFFFAOYSA-N 2,3-dihydro-1h-1-benzazepine Chemical compound N1CCC=CC2=CC=CC=C21 WSSWXGZEJNNFSN-UHFFFAOYSA-N 0.000 description 1
- YSFBEAASFUWWHU-UHFFFAOYSA-N 2,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C(Cl)=C1 YSFBEAASFUWWHU-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- DZIQDBROLFSEQQ-UHFFFAOYSA-N 2-(2-sulfanylidene-3h-1,3,4-thiadiazol-5-yl)ethanethioic s-acid Chemical compound OC(=S)CC1=NN=C(S)S1 DZIQDBROLFSEQQ-UHFFFAOYSA-N 0.000 description 1
- BLRXDBRXRDDUFQ-UHFFFAOYSA-N 2-(4-methoxycarbonylphenyl)ethanethioic s-acid Chemical compound COC(=O)C1=CC=C(CC(O)=S)C=C1 BLRXDBRXRDDUFQ-UHFFFAOYSA-N 0.000 description 1
- KYBOCQHDFLVQIB-UHFFFAOYSA-N 2-(4-methyl-2-sulfanylidene-3h-1,3-thiazol-5-yl)acetic acid Chemical compound CC=1N=C(S)SC=1CC(O)=O KYBOCQHDFLVQIB-UHFFFAOYSA-N 0.000 description 1
- SYQOBXMNPFJLMH-UHFFFAOYSA-N 2-(5-methoxycarbonylpyrimidin-2-yl)ethanethioic s-acid Chemical compound COC(=O)C1=CN=C(CC(O)=S)N=C1 SYQOBXMNPFJLMH-UHFFFAOYSA-N 0.000 description 1
- WTICDNRPORVGET-UHFFFAOYSA-N 2-(6-methoxycarbonylnaphthalen-2-yl)ethanethioic s-acid Chemical compound C1=C(CC(O)=S)C=CC2=CC(C(=O)OC)=CC=C21 WTICDNRPORVGET-UHFFFAOYSA-N 0.000 description 1
- DRZIZNYOPFSEDH-UHFFFAOYSA-N 2-(fluoromethyl)pyrimidine Chemical compound FCC1=NC=CC=N1 DRZIZNYOPFSEDH-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- BYIDGAOFXDSJJI-UHFFFAOYSA-N 2-[4-(2-ethoxy-2-oxoethyl)phenyl]ethanethioic s-acid Chemical compound CCOC(=O)CC1=CC=C(CC(O)=S)C=C1 BYIDGAOFXDSJJI-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- MWPNPNLDBXDQCC-UHFFFAOYSA-N 2-amino-3-(diethylamino)propanoic acid Chemical compound CCN(CC)CC(N)C(O)=O MWPNPNLDBXDQCC-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- HTCSFFGLRQDZDE-UHFFFAOYSA-N 2-azaniumyl-2-phenylpropanoate Chemical compound OC(=O)C(N)(C)C1=CC=CC=C1 HTCSFFGLRQDZDE-UHFFFAOYSA-N 0.000 description 1
- IMRXCWIIGSLQJA-UHFFFAOYSA-N 2-bromo-7-nitro-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC(Br)C(=O)C2=CC([N+](=O)[O-])=CC=C21 IMRXCWIIGSLQJA-UHFFFAOYSA-N 0.000 description 1
- TXNVFBQVMHDSMV-UHFFFAOYSA-N 2-butoxyethyl hydrogen carbonate Chemical compound CCCCOCCOC(O)=O TXNVFBQVMHDSMV-UHFFFAOYSA-N 0.000 description 1
- VCBFAUSKNYAKJZ-UHFFFAOYSA-N 2-chloro-3-oxobutanoic acid Chemical compound CC(=O)C(Cl)C(O)=O VCBFAUSKNYAKJZ-UHFFFAOYSA-N 0.000 description 1
- XDMZVNQKVMTCSP-UHFFFAOYSA-N 2-fluoro-3-(trifluoromethyl)benzaldehyde Chemical compound FC1=C(C=O)C=CC=C1C(F)(F)F XDMZVNQKVMTCSP-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- IXOFPUCWZCAFJX-UHFFFAOYSA-N 2-phenylethanethioic s-acid Chemical compound SC(=O)CC1=CC=CC=C1 IXOFPUCWZCAFJX-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 description 1
- CASRSOJWLARCRX-UHFFFAOYSA-N 3,5-dichlorobenzaldehyde Chemical compound ClC1=CC(Cl)=CC(C=O)=C1 CASRSOJWLARCRX-UHFFFAOYSA-N 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YQWPHBFLHAJVCG-UHFFFAOYSA-N 3-(4-sulfanylphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(S)C=C1 YQWPHBFLHAJVCG-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- SONNQRNOTIAJDS-GFCCVEGCSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(2R)-2,3-dihydroxypropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC[C@H](CO)O)C=CC=1 SONNQRNOTIAJDS-GFCCVEGCSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- OJFQNFVCICBYQC-UHFFFAOYSA-N 3-chloro-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1Cl OJFQNFVCICBYQC-UHFFFAOYSA-N 0.000 description 1
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- NWUYAYVDHURYQU-UHFFFAOYSA-N 3-methoxy-1h-pyridazine-6-thione Chemical compound COC1=CC=C(S)N=N1 NWUYAYVDHURYQU-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 description 1
- JLAMDELLBBZOOX-UHFFFAOYSA-N 3h-1,3,4-thiadiazole-2-thione Chemical compound SC1=NN=CS1 JLAMDELLBBZOOX-UHFFFAOYSA-N 0.000 description 1
- FPSPPRZKBUVEJQ-UHFFFAOYSA-N 4,6-dimethoxypyrimidine Chemical compound COC1=CC(OC)=NC=N1 FPSPPRZKBUVEJQ-UHFFFAOYSA-N 0.000 description 1
- DJJLKDMESZPSAM-UHFFFAOYSA-N 4-(1,3-thiazol-4-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CSC=N1 DJJLKDMESZPSAM-UHFFFAOYSA-N 0.000 description 1
- BJZQKHKNZBGSOX-UHFFFAOYSA-N 4-[(2,4-dichlorophenyl)methyl]morpholine Chemical compound ClC1=CC(Cl)=CC=C1CN1CCOCC1 BJZQKHKNZBGSOX-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- WCDSVWRUXWCYFN-UHFFFAOYSA-N 4-aminobenzenethiol Chemical compound NC1=CC=C(S)C=C1 WCDSVWRUXWCYFN-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- VFPFMOXMHVQFNR-UHFFFAOYSA-N 4-chlorothieno[3,2-c]pyridine Chemical compound ClC1=NC=CC2=C1C=CS2 VFPFMOXMHVQFNR-UHFFFAOYSA-N 0.000 description 1
- GLUKYMLNGXPGFR-UHFFFAOYSA-N 4-cyclopentylbutanethioic s-acid Chemical compound SC(=O)CCCC1CCCC1 GLUKYMLNGXPGFR-UHFFFAOYSA-N 0.000 description 1
- LFLSATHZMYYIAQ-UHFFFAOYSA-N 4-flourobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(F)C=C1 LFLSATHZMYYIAQ-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- NWOPHJSSBMABBD-QRPNPIFTSA-N 4-methylbenzenesulfonate;[(2s)-1-oxo-1-phenylmethoxypropan-2-yl]azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C[C@H](N)C(=O)OCC1=CC=CC=C1 NWOPHJSSBMABBD-QRPNPIFTSA-N 0.000 description 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
- LMJXSOYPAOSIPZ-UHFFFAOYSA-N 4-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=C(S)C=C1 LMJXSOYPAOSIPZ-UHFFFAOYSA-N 0.000 description 1
- WSWWYTGGNKIPSK-UHFFFAOYSA-N 4h-indeno[1,2-d][1,3]thiazole Chemical compound C1C2=CC=CC=C2C2=C1SC=N2 WSWWYTGGNKIPSK-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KSONICAHAPRCMV-UHFFFAOYSA-N 5-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=C2C(=O)CCC2=C1 KSONICAHAPRCMV-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RGTBLCLLSZPOKR-UHFFFAOYSA-N 5-methyl-1,2,4-oxadiazole Chemical compound CC1=NC=NO1 RGTBLCLLSZPOKR-UHFFFAOYSA-N 0.000 description 1
- FPVUWZFFEGYCGB-UHFFFAOYSA-N 5-methyl-3h-1,3,4-thiadiazole-2-thione Chemical compound CC1=NN=C(S)S1 FPVUWZFFEGYCGB-UHFFFAOYSA-N 0.000 description 1
- NVKJOXRVEKMMHS-UHFFFAOYSA-N 5-nitro-1,2,4-triazol-3-one Chemical compound [O-][N+](=O)C1=NC(=O)N=N1 NVKJOXRVEKMMHS-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- LIIQAABLAWXNJJ-UHFFFAOYSA-N 6,7-dimethoxyquinazoline Chemical compound C1=N[C]2C=C(OC)C(OC)=CC2=C=N1 LIIQAABLAWXNJJ-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- LVOYSBZJJWPUBD-UHFFFAOYSA-N 6-(trifluoromethyl)-1h-pyrimidin-4-one Chemical compound OC1=CC(C(F)(F)F)=NC=N1 LVOYSBZJJWPUBD-UHFFFAOYSA-N 0.000 description 1
- HDGJASCXBNRLGA-UHFFFAOYSA-N 6-(trifluoromethyl)-1h-pyrimidine-2-thione Chemical compound FC(F)(F)C1=CC=NC(S)=N1 HDGJASCXBNRLGA-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- IDPNFKLUBIKHSW-UHFFFAOYSA-N 6-amino-3h-1,3-benzothiazole-2-thione Chemical compound NC1=CC=C2N=C(S)SC2=C1 IDPNFKLUBIKHSW-UHFFFAOYSA-N 0.000 description 1
- IAZWESCHJCWOSL-UHFFFAOYSA-N 6-fluoronaphthalene-2-carbaldehyde Chemical compound C1=C(C=O)C=CC2=CC(F)=CC=C21 IAZWESCHJCWOSL-UHFFFAOYSA-N 0.000 description 1
- UQJLPBLXSJWAKG-UHFFFAOYSA-N 6-methyl-1h-pyrimidin-3-ium-2-thione;chloride Chemical compound Cl.CC1=CC=NC(=S)N1 UQJLPBLXSJWAKG-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- JWWGTYCXARQFOT-UHFFFAOYSA-N 6-sulfanylidene-1h-pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(S)N=C1 JWWGTYCXARQFOT-UHFFFAOYSA-N 0.000 description 1
- ODPYDILFQYARBK-UHFFFAOYSA-N 7-thiabicyclo[4.1.0]hepta-1,3,5-triene Chemical compound C1=CC=C2SC2=C1 ODPYDILFQYARBK-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- CLBCFDSAZHXNIN-UHFFFAOYSA-N 8-nitro-4,5-dihydro-1H-benzo[e][1,3]benzothiazole-2-thione Chemical compound SC=1SC2=C(N1)C1=CC(=CC=C1CC2)[N+](=O)[O-] CLBCFDSAZHXNIN-UHFFFAOYSA-N 0.000 description 1
- MTVNAPYHLASOSX-UHFFFAOYSA-N 9,9-dimethylxanthene Chemical compound C1=CC=C2C(C)(C)C3=CC=CC=C3OC2=C1 MTVNAPYHLASOSX-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- LVSDLZIEHYYLTC-UHFFFAOYSA-N Butanoic acid, 2,2-dimethyl-3-oxo-, methyl ester Chemical compound COC(=O)C(C)(C)C(C)=O LVSDLZIEHYYLTC-UHFFFAOYSA-N 0.000 description 1
- MUQBELMLRXWHOL-MRXNPFEDSA-N C(C)(=O)NSC1=CC=C(C=C1)S(NC[C@@H]1CN(CCO1)CC1=CC(=C(C=C1)Cl)Cl)(=O)=O Chemical compound C(C)(=O)NSC1=CC=C(C=C1)S(NC[C@@H]1CN(CCO1)CC1=CC(=C(C=C1)Cl)Cl)(=O)=O MUQBELMLRXWHOL-MRXNPFEDSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 1
- 101150019010 CCR3 gene Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- WVDYBOADDMMFIY-UHFFFAOYSA-N Cyclopentanethiol Chemical compound SC1CCCC1 WVDYBOADDMMFIY-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000277306 Esocidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 101700012268 Holin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- HDJLSECJEQSPKW-UHFFFAOYSA-N Methyl 2-Furancarboxylate Chemical compound COC(=O)C1=CC=CO1 HDJLSECJEQSPKW-UHFFFAOYSA-N 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- VSYXRMYWASBQMG-KPMSDPLLSA-N N-[[(2S)-1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2H-pyrimidin-2-yl]sulfanyl]acetamide Chemical compound C(C)(=O)NS[C@H]1N(C=CC=N1)CC1CN(CCO1)CC1=CC(=C(C=C1)Cl)Cl VSYXRMYWASBQMG-KPMSDPLLSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- FMZOFALNKRKXST-UHFFFAOYSA-N OC(=O)SC1=NC=CS1 Chemical group OC(=O)SC1=NC=CS1 FMZOFALNKRKXST-UHFFFAOYSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 description 1
- SWEDAZLCYJDAGW-UHFFFAOYSA-N Thiophene-2-thiol Chemical compound SC1=CC=CS1 SWEDAZLCYJDAGW-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000005628 Triflusulfuron Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- DWKBWTXQPMQQLO-JTQLQIEISA-N [(2s)-4-[(3,4-difluorophenyl)methyl]morpholin-2-yl]methanamine Chemical compound C1CO[C@@H](CN)CN1CC1=CC=C(F)C(F)=C1 DWKBWTXQPMQQLO-JTQLQIEISA-N 0.000 description 1
- MZYIVSVTSOQNLT-XRIOVQLTSA-N [(2s)-4-[(3,4-difluorophenyl)methyl]morpholin-2-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1CO[C@@H](CN)CN1CC1=CC=C(F)C(F)=C1 MZYIVSVTSOQNLT-XRIOVQLTSA-N 0.000 description 1
- DIPHRHKNVZTXSG-LTCKWSDVSA-N [(2s)-4-[(3-chlorophenyl)methyl]morpholin-2-yl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1CO[C@@H](CN)CN1CC1=CC=CC(Cl)=C1 DIPHRHKNVZTXSG-LTCKWSDVSA-N 0.000 description 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- IHTYTYHXCRAMAV-UHFFFAOYSA-N acetic acid;dihydrochloride Chemical compound Cl.Cl.CC(O)=O IHTYTYHXCRAMAV-UHFFFAOYSA-N 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- IMIDOCRTMDIQIJ-UHFFFAOYSA-N aminocarb Chemical compound CNC(=O)OC1=CC=C(N(C)C)C(C)=C1 IMIDOCRTMDIQIJ-UHFFFAOYSA-N 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940054021 anxiolytics diphenylmethane derivative Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- PWLNAUNEAKQYLH-UHFFFAOYSA-N butyric acid octyl ester Natural products CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- HYNDQCLDXZXZIT-UHFFFAOYSA-N chloroethane;propanedioic acid Chemical compound CCCl.OC(=O)CC(O)=O HYNDQCLDXZXZIT-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical class O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- 125000004978 cyclooctylene group Chemical group 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- RKXWKTOBQOSONL-UHFFFAOYSA-N ethyl 1,2-oxazole-3-carboxylate Chemical compound CCOC(=O)C=1C=CON=1 RKXWKTOBQOSONL-UHFFFAOYSA-N 0.000 description 1
- XDOKFEJMEJKVGX-UHFFFAOYSA-N ethyl 1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC=N1 XDOKFEJMEJKVGX-UHFFFAOYSA-N 0.000 description 1
- OTMKLBXQEYBHJE-UHFFFAOYSA-N ethyl 2-(1,3-thiazol-2-yl)acetate Chemical compound CCOC(=O)CC1=NC=CS1 OTMKLBXQEYBHJE-UHFFFAOYSA-N 0.000 description 1
- LBUCJPLWPDHVOH-QWAKEFERSA-N ethyl 2-[(2S)-2-acetamidosulfanyl-3-[[4-[(3,5-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2H-1,3-thiazol-4-yl]acetate Chemical compound C(C)(=O)NS[C@@H]1SC=C(N1CC1CN(CCO1)CC1=CC(=CC(=C1)Cl)Cl)CC(=O)OCC LBUCJPLWPDHVOH-QWAKEFERSA-N 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- PCPIANOJERKFJI-UHFFFAOYSA-N ethyl 5-bromopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=CC(Br)=C1 PCPIANOJERKFJI-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- JZGZKRJVTIRPOK-UHFFFAOYSA-N ethyl thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=CS1 JZGZKRJVTIRPOK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- REHUGJYJIZPQAV-UHFFFAOYSA-N formaldehyde;methanol Chemical compound OC.O=C REHUGJYJIZPQAV-UHFFFAOYSA-N 0.000 description 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N iso-butene Natural products CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- UGPSGKBXOZVVCV-UHFFFAOYSA-N n-(morpholin-2-ylmethyl)acetamide Chemical compound CC(=O)NCC1CNCCO1 UGPSGKBXOZVVCV-UHFFFAOYSA-N 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- AXVSPJDWWCYULK-BIAFCPFJSA-N n-[[(2s)-3-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-4-(3,4-dimethoxyphenyl)-2h-1,3-thiazol-2-yl]sulfanyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CS[C@@H](SNC(C)=O)N1CC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 AXVSPJDWWCYULK-BIAFCPFJSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005184 naphthylamino group Chemical group C1(=CC=CC2=CC=CC=C12)N* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NHXJORYYNYGBNF-UHFFFAOYSA-N o-methyl 2-(2,6-dimethoxypyrimidin-4-yl)ethanethioate Chemical compound COC(=S)CC1=CC(OC)=NC(OC)=N1 NHXJORYYNYGBNF-UHFFFAOYSA-N 0.000 description 1
- WNCPYOMYFOCMHL-UHFFFAOYSA-N o-methyl 2-(4-sulfamoylphenyl)ethanethioate Chemical compound COC(=S)CC1=CC=C(S(N)(=O)=O)C=C1 WNCPYOMYFOCMHL-UHFFFAOYSA-N 0.000 description 1
- KNVXWCYHEXKEQS-UHFFFAOYSA-N o-methyl 2-(6-chloropyridazin-3-yl)ethanethioate Chemical compound COC(=S)CC1=CC=C(Cl)N=N1 KNVXWCYHEXKEQS-UHFFFAOYSA-N 0.000 description 1
- QSKJIQNEKNNWBQ-UHFFFAOYSA-N o-methyl 2-pyrazin-2-ylethanethioate Chemical compound COC(=S)CC1=CN=CC=N1 QSKJIQNEKNNWBQ-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical compound P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical group CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 1
- ZPATUOFYXSBHMN-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [H+].[H+].[H+].[Br-].[Br-].[Br-].C1=CC=NC=C1 ZPATUOFYXSBHMN-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- XOVSRHHCHKUFKM-UHFFFAOYSA-N s-methylthiohydroxylamine Chemical compound CSN XOVSRHHCHKUFKM-UHFFFAOYSA-N 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- ZRRGOUHITGRLBA-UHFFFAOYSA-N stattic Chemical compound [O-][N+](=O)C1=CC=C2C=CS(=O)(=O)C2=C1 ZRRGOUHITGRLBA-UHFFFAOYSA-N 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- OSWULUXZFOQIRU-UHFFFAOYSA-N tert-butyl 2-aminoacetate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CN OSWULUXZFOQIRU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- AKTQJCBOGPBERP-UHFFFAOYSA-N triflusulfuron Chemical compound FC(F)(F)COC1=NC(N(C)C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2C)C(O)=O)=N1 AKTQJCBOGPBERP-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- ZNEOHLHCKGUAEB-UHFFFAOYSA-N trimethylphenylammonium Chemical compound C[N+](C)(C)C1=CC=CC=C1 ZNEOHLHCKGUAEB-UHFFFAOYSA-N 0.000 description 1
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel morpholine compound having an affinity for CCR 3, the compound or a salt thereof is a disease in which cells having CCR 3 play an important role in the onset, progression, and maintenance of pathological conditions, For example, as a therapeutic and / or preventive for asthma, sinusitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, allergic myelitis, ulcerative colitis, Crohn's disease, rheumatoid arthritis, etc. Useful.
- chemotactic substance that induces migration and local infiltration of leukocytes such as neutrophils and monocytes, arachidonic acid metabolism such as complement degradation products C 3 a and 5a, le uk otriene B 4 etc.
- Classic chemotactic factors such as products, platelet-activating factor, and bacterially-formylated peptides. These are secondary products mainly associated with tissue injury.
- chemokines a series of cytokines produced by new gene expression and responsible for the induction and activation of specific leukocytes, so-called chemokines, were purified in 1987 by Matsushima et al. (Interle uk in (IL))-8 (CXCL8) has been proven to exist (eg Proc. Natl. Acad. Sci. USA, 84, 9223-9237 (1987) and J ". Exp. Med. , 167, 1883-1893 (1988)).
- chemokines have been identified, and chemokines are classified into four subgroups based on their amino acid sequence characteristics. That is, C chemokine, CC chemokine,. . It's a chemokine and 3 chemokines.
- XC L 1 belonging to the C chemokine exhibits a migration activity against T cells and NK cells.
- CC chemokines exhibit migratory activity against monocytes other than neutrophils, lymphocytes, Langerhans cells, dendritic cells, eosinophils, mast cells and basophils.
- CXC chemokines as represented by CXCL 8, mainly affect neutrophils
- CX 3 C chemokines mainly affect NK cell migration.
- These chemokines exert their actions by binding to G protein-coupled receptors (chemokine receptors).
- chemokine receptors G protein-coupled receptors
- a substance that inhibits the binding between chemokine and its receptor suppresses the selective migration and activity of leukocytes, and prevents or treats acute and chronic inflammatory diseases including allergic diseases. It is considered useful as a pharmaceutical product.
- Eosinophil infiltration into inflamed tissue is included. Therefore, eosinophils are thought to play an important role in the onset, progression and maintenance of these diseases. It is known that CCR 3, which is a receptor for CC chemokine, plays an important role in the activation of eosinophils in the local area of inflammation. As well as inflammatory cells such as mast cells, basophils, dendritic cells and Th 2 cells (J. Clin.
- compounds having affinity for CCR 3 can be expected to be useful as pharmaceuticals for the prevention or treatment of immune and inflammatory diseases.
- Heteroaromatic derivatives of the ring system, etc., W099 / 55324 and WO 99/55330 have affinity for chemokine receptors, such as phenylalanine derivatives WO00 no 58305 have affinity for chemokine receptors
- Piperazine derivatives such as WO 00/31033, WO 00-53600, WO 01/143 33, WO02 / 66460, and WO 02/881 11 include piperidine derivatives having affinity for chemokine receptors. Etc. are disclosed.
- WO02 / 1 8335 discloses a cyclic amine derivative having a CCR 3 antagonistic action.
- WO 02/26722, WO 02/26723, WO 03/82292, WO 03/82294, WO 03/82861, WO 03/82862, WO 0-3 82295, WO 03/82863, WO 03/99287, and WO 03/99798 discloses morpholine derivatives having affinity for chemokine receptors and the like. However, these compounds do not have the structural features (that is, compounds having a sulfur atom at the tip of the alkylene chain from the morpholine ring via the methylene amide) as a preferred embodiment of the compound of the present invention described later.
- CCR 3 antagonists with different structures are considered to be acute, including immune and allergic diseases. It is expected to be a drug for the treatment or prevention of chronic inflammatory diseases.
- An object of the present invention is to provide a pharmaceutical product having affinity for CCR3 and for the treatment and / or prevention of immune and inflammatory diseases.
- the present inventors have conducted extensive studies to find a non-peptide compound exhibiting a CCR3 antagonistic action. It has been found that the pharmaceutically acceptable salts of these compounds, or their hydrates or solvates inhibit the binding of CCR3 to its ligand and act as antagonists. Therefore, the present invention was completed by finding that the compound of the present invention can be a pharmaceutical for the treatment or prevention of acute and chronic inflammatory diseases including immunity and allergic diseases.
- the gist of the present invention is as follows.
- Ring A represents an aryl which may have a substituent, or a heteroaryl which may have a substituent,
- Ring B may have a substituent group Ariren, 2 may have a substituent 3 ⁇ 4 valence of heterocyclic group, or an optionally C 3 _ 8 cycloalkylene which may have a substituent , M represents an integer from 0 to 2,
- n an integer from 1 to 5
- X is a bond, 1 NH—, 1 NR 1 — (wherein R 1 represents C 6 alkyl optionally having a substituent), —CO—, 1 CO 2 —, — OCO—, -CONR a-
- R a represents a hydrogen atom or C 6 alkyl optionally having a substituent.
- R 2 R 3 may be the same or different and each may have a hydrogen atom or a substituent, and represents 0 to 6 alkyl, or an atom to which R 2 and R 3 are bonded together And may form a ring which may have a substituent.
- Y represents a bond, one NH—, —NR 4 — (wherein R 4 represents an optionally substituted C 6 alkyl. The same shall apply hereinafter.), One CO—, one C0 2 —, 1 OCO—, 1 CO N 3 ⁇ 4- (wherein R b represents a hydrogen atom or an alkyl which may have a substituent. The same shall apply hereinafter.), 1 NR b CO—, 1 NR 5 CONR 6 — (In the formula, R 5 and R 6 may be the same or different and each represents a hydrogen atom or C 6 alkyl optionally having a substituent. Alternatively, R 5 and R 6 are combined together.
- Z represents a hydrogen atom, a halogen atom, which may have a substituent - 6 alkyl, which may have a location substituent 0 3 _ 8 cycloalkyl, optionally ⁇ Li may have a substituent Group, optionally substituted heterocyclic group, hydroxy, nitro, amino, cyano, optionally substituted alkoxy, optionally substituted mono or di . 6 Arukiruamino may have a substituent. 7 Asylua Mino, optionally substituted sulfonylamino, optionally substituted hydrazino, optionally substituted guanidino or optionally substituted amidino . ]
- Ring B is an arylene which may have a substituent, or a divalent heterocyclic group which may have a substituent,
- X is a bond, 1 NH—, 1 NR 1 — (wherein R 1 may have a substituent; 6 represents alkyl), — CO—, — C0 2 —, — OCO —, —CONR a — (In the formula, R a represents a hydrogen atom or a C 6 alkyl optionally having a substituent. The same shall apply hereinafter.), NR a CO—, —N 2 CONR 3 — (Wherein R 2 and R 3 may be the same or different and each represents a hydrogen atom or an alkyl which may have a substituent.
- R 2 and R 3 together represent , Oxygen atom, sulfur atom, —SO—, one S0 2 —, one NR a S0 2 —, one S0 2 NR a -, alkylene 6 which may have a substituent, which may have a substituent C 2 - 6 Aruke - Ren, good C 2 _ 6 alkylene which may have a substituent - Ren, one O- X a (X a in the formula represents an alkylene optionally have a substituent or less the same..), One X a - O-, -CO- X a -, one X a - CO-, one CONR a - X a ⁇ , 1 X a — CONR a ⁇ , 1 NR a CO— X a ⁇ , 1 — NR a CO—, 1 S— X a —, 1 X a — S—, 1 SO— X a —, 1
- X is a bond, one NH—, —NR 1 — (wherein R 1 represents an alkyl which may have a substituent), one CO—, 1 C0 2 —, — OCO—, 1 CONR a — (wherein R a represents a hydrogen atom or C 6 alkyl which may have a substituent.
- 1 NR a CO— , -N 2 CONR 3 (wherein R 2 and R 3 may be the same or different and each represents a hydrogen atom or a Ci-e alkyl optionally having a substituent), oxygen Atom, Sulfur atom, One SO—, One S0 2 —, One NR a S0 2 —, One S0 2 NR a —, optionally substituted C 2 — 6 alkerene, One CO— X a — (In the formula, X a represents alkylene which may have a substituent.
- Which may be C 3 - 8 cycloalkylidene a is the above-mentioned [1] to a compound or a pharmaceutically acceptable salt thereof of the mounting serial any one of [4] or their hydrate or solvate thereof.
- X represents a bond, one CO—, —CONR a — (wherein R a represents a hydrogen atom or an optionally substituted alkyl. The same shall apply hereinafter. ), 1 NR a CO—, 1 CO— X a — (wherein X a represents C 6 alkylene which may have a substituent. The same shall apply hereinafter.), 1 X a — CO—,
- Y is a bond, 1 NH—, 1 NR 4 — (wherein R 4 represents an optionally substituted C 6 alkyl), — CO—, —C0 2 —, 1 OCO—, 1 CONR b — (wherein R b represents a hydrogen atom or an optionally substituted C 6 alkyl; the same shall apply hereinafter), 1 NR b CO—, 1 NR 5 CONR 6 — (wherein R 5 and R 6 may be the same or different and each represents a hydrogen atom or The alkyl which may have a substituent is shown.
- Y represents a bond, one CO—, —CONR b — (wherein R b represents a hydrogen atom or an alkyl which may have a substituent. The same shall apply hereinafter. .), one NR b CO-, one CO- X b -..
- X b in the formula represents a C ⁇ one 6 alkylene which may have a substituent hereinafter the same), one X b - CO-,
- Z is a hydrogen atom, a halogen atom, Ci-e alkyl optionally having substituent, which may have a substituent C 3 - 8 cycloalkyl, substituted An optionally substituted aryl, an optionally substituted heterocyclic group, a hydroxy, a nitro, an amino, a cyano, an optionally substituted — 6 alkoxy, a substituted group Mono- or di-alkylamino optionally having a substituent, C- 7 acylamino optionally having a substituent, sulfonylamino optionally having a substituent, hydrazino optionally having a substituent,
- the compound or a pharmaceutically acceptable salt thereof according to any one of the above (1) to (8), which is an optionally substituted guanidino, or an optionally substituted amidino, or Their hydrates or solvates.
- Z may have a hydrogen atom, hydroxy, amino, an optionally substituted alkyl, or an optionally substituted group.
- (6 ) The compound according to any one of (1) to (9) above, which is an alkoxy, an optionally substituted aryl, or an optionally substituted heterocyclic group, or a pharmaceutically acceptable salt thereof. Or a hydrate or solvate thereof.
- (la) The compound according to any one of (1) to (9) above, which is an alkoxy, an optionally substituted aryl, or an optionally substituted heterocyclic group, or a pharmaceutically acceptable salt thereof. Or a hydrate or solvate thereof.
- ring c represents aryl or heteroaryl which may have a substituent, and other symbols are as defined above in [1].
- n is 1 to 3, the compound according to any one of the above [1] to [: 12], or a pharmaceutically acceptable salt thereof, or a hydrate thereof, Solvate.
- the absolute configuration at the 2-position of morpholine is the S configuration, the compound according to any one of the above [1] to [13], or a pharmaceutically acceptable salt thereof, or water thereof Japanese solvate or solvate.
- a CCR3 antagonist comprising the compound according to any one of [1] to [15] above or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient.
- a pharmaceutical composition comprising the compound according to any one of [1] to [15] above, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutically acceptable carrier. .
- [19] comprising administering an effective amount of the compound according to any one of [1] to [15] above or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof to an animal
- the disease involving CCR 3 is asthma, sinusitis, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, allergic myelitis, ulcerative colitis, Crohn's disease or rheumatoid arthritis
- Ring B may ⁇ Li one Ren may have a substituent, 2 may have a substituent monovalent
- n an integer from 1 to 5
- X is a bond, 1 NH—, —NR 1 — (wherein R 1 represents an optionally substituted C 6 alkyl), —CO_, —C0 2 —, —OCO—, One CONR a —
- R a represents a hydrogen atom or an alkyl which may have a substituent.
- NR a CO—, —NR 2 CONR 3 — (where R 2 , R 3 Are the same or different and each represents a hydrogen atom or 6 alkyl optionally having a substituent, or R 2 and R 3 together and the atom to which they are bonded together ), Oxygen atom, sulfur atom, —SO—, — S0 2 —, one NR a S0 2 —, — S0 2 NR a —, a substituent alkylene which may have, which may have a substituent C 2 - 6 alkenylene, substituents which may have C 2 - 6 alkynylene one O- X a - (X a in the formula May have a substituent — 6 represents alkylene, the same shall apply hereinafter)), one X a — O—, one CO— X a —,
- Y represents a bond, one NH—, —NR 4 — (wherein R 4 represents an optionally substituted C 6 alkyl. The same shall apply hereinafter.), One CO—, one co 2 —, One OCO—, —CO NR b — (wherein R b represents a hydrogen atom or an alkyl which may have a substituent. The same shall apply hereinafter.), One NR b CO—, —NR 5 CONR 6 — (In the formula, R 5 and 6 may be the same or different and each represents a hydrogen atom or a Ci_ 6 alkyl which may have a substituent. Alternatively, R 5 and R 6 are taken together.
- Z represents a hydrogen atom, a halogen atom, which may have a substituent C 6 alkyl which may have a location substituent C 3 - 8 cycloalkyl, optionally ⁇ Li may have a substituent Group, optionally substituted heterocyclic group, hydroxy, nitro, amino, cyano, optionally substituted Ci-e alkoxy, optionally substituted mono- or di - C i-6 alkylamino, substituents one may have a 7 Ashirua amino, which may have a substituent sulfo - Ruamino, which may have a substituent hydrazino, substituted Guanidino which may have a group or amidino which may have a substituent. Or a salt thereof and a general formula (8)
- ring A represents an aryl which may have a substituent, or an heteroaryl which may have a substituent.
- diseases in which cells having CCR 3 play an important role in the onset, progression and maintenance of pathological conditions such as asthma, sinusitis, allergic rhinitis, atopic dermatitis, allergy
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- aryl in “optionally substituted aryl” means a monocyclic to tricyclic ring.
- 0 6 _ 1 4 means aryl, for example, phenyl, naphthyl, anthryl, indenyl, etc., preferred examples include phenyl, naphthyl, etc., more preferred examples include phenyl. .
- aryls may be partially hydrogenated.
- the position to be hydrogenated is not particularly limited. Examples of partially hydrogenated aryls include tetrahydronaphthyl and indanole.
- aryl has “substituent”, the type and number thereof are not particularly limited, and “substituent” force defined below, one selected substituent at the substitutable position Have four.
- substituents that the aryl may have include a halogen atom, cyano, nitro, Ci- 6 alkyl, C- 6 haloalkyl, 6 alkoxy, hydroxy, amino, mono- or di-acyl) amino, carboxy, - 6 alkoxy one carbo - le, Karupamoiru, hydroxyamidino and the like, more preferably a chlorine atom as an example, a fluorine atom, Shiano, nitro, methyl, tri Furuoromechiru, main butoxy, human Dorokishi, amino, Asechiruamino , Carboxy, methoxycarboel, carbamoyl, hydroxyamidino, more preferable examples include fluorine atom, chlorine atom, methyl or trifluoromethyl, and still
- Heteroaryl in “optionally substituted heteroaryl” refers to 1 to 3 heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to a carbon atom as a ring atom.
- heteroaryl is a 5- to 7-membered member containing 1 to 4 heteroatoms selected from nitrogen, sulfur and oxygen atoms in addition to carbon atoms as ring atoms.
- groups derived from aromatic heterocycles (bicyclic or higher) formed by condensation of aromatic heterocycles with benzene rings or the above aromatic heterocycle (monocyclic) groups for example, indolyl, isoindolyl Benzo [b] furyl, benzo [b] cenyl, benzoimidazolyl, benzoxazolinole, benzoisoxazoly / re, benzothiazoly / re, benzoisothiazolyl, quinolyl, isoquinolyl and the like.
- heteroaryls may be partially hydrogenated.
- the position to be hydrogenated is not particularly limited.
- examples of the partially hydrogenated heteroaryl include tetrahydrobenzoimidazolyl, tetrahydroquinolyl, tetrahydroquinol isoquinolyl and the like.
- heteroaryl examples include furyl, chael, thiazolyl, pyridinole, indolyl, benzo [b] furyl, benzo [b] chell, benzoxazolinole, benzothiazolyl, quinolyl, isoquinolyl, and more Preferable examples include furyl, chael, thiazolyl and pyridyl.
- heteroaryl force S “substituent”
- the type and number thereof are not particularly limited, and one substituent selected from “substituent” defined below can be substituted at one of the substitutable positions.
- Preferable examples of the substituent which the heteroaryl may have include a halogen atom, cyano and nitro, and more preferable examples include a halogen atom.
- arylene in the “arylene optionally having a substituent” means a divalent group further having a bond at an arbitrary position of the above “aryl”, for example, phenylene, And divalent groups such as naphthylene and indenylene.
- arylenes may be partially hydrogenated. Position to be hydrogenated Is not particularly limited. Examples of the partially hydrogenated arylene include tetrahydronaphthylene and indanylene.
- arylene examples include phenylene, naphthylene, indanylene and the like, and more preferable examples include phenylene and the like.
- the “arylene” has a substituent
- the kind and number thereof are not particularly limited, and 1 to 3 substituents selected from the “substituent” defined below are present at substitutable positions.
- substituents that arylene may have include Ci-ealkyl, Ci-ealkoxy, hydroxy, oxo and the like, and more preferable examples include oxo. it can.
- heterocyclic group in “an optionally substituted divalent heterocyclic group” in ring B and “an optionally substituted heterocyclic group” in Z is ring Atom containing 1 to 4 types of heteroatoms selected from nitrogen, sulfur and oxygen atoms in addition to carbon atoms 5- to 4-membered monocyclic to tricyclic heterocycles Means a group.
- Heterocyclic group includes saturated rings, aromatic rings (including “heteroaryl” as defined above), and partially hydrogenated ring groups thereof.
- Partially hydrogenated heteroaryls include, for example, dihydrofuryl, dihydrocenyl, pyrrolinyl, thiazolinyl, biazolinyl, oxazolinyl, isoxazolinyl, isothiazolinyl, imidazolinyl, 1, 2, 4-oxadiazolinyl, 1, 3, 4—oxadiazolinyl, 1, 2, 3—triazolinyl, 1, 2, 4—triazolinyl, 1, 2, 4—thiadiazolinyl, 1, 3, 4—thiadiazolinyl, dihydropyridazinyl, tetrahydro Examples include benzoimidazolyl, tetrahydroquinolyl, tetrahydroisoquinolyl and the like.
- heterocyclic group examples include pyrrolidyl, piperidyl, piperazinyl, tetrahydrofuranyl, monolepholinyl, thiazolidyl, thiomorpholinyl, homopiperagel and the like.
- heterocyclic group includes “bridged hetero ring group” containing 1 to 4 hetero atoms selected from oxygen atom, sulfur atom and nitrogen atom in addition to carbon atom as ring atom.
- bridging ring group examples include 3-azabicyclo [3.2.2] nonane-1-yl, 8-azabicyclo [3.2. 1] One octane 8-yl.
- heterocyclic group has a “substituent”, the kind and number thereof are not particularly limited, and one substituent selected from the “substituent” defined below is located at the substitutable position. ⁇ 4 have.
- substituent that the heterocyclic group may have include C 6 alkyl, hydroxy, nitro, amino, cyano, carboxy, alkoxyl alkenyl, carbamoyl, oxo and the like. Ethoxycarbonyl, carbamoyl and oxo are more preferred.
- heterocyclic group examples include pyridyl, bilazyl, jellimidyl, pyridazyl, imidazolyl, pyrrolyl, pyrrolidyl, morpholyl, chael, furyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl Quinolyl, isoquinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, quinolizinyl, quinazolyl, quinoxalinyl, cinnolinole, phthalazine, 1,8-naphthyridinyl, attaridinyl, purinyl, pteridinyl, 1,2,4 Oxadiazolinyl, 1, 3, 4-oxadiazolyl, 1, 2, 3-triazolyl, 1, 2, 4-triazolyl, 1, 3, 5-triazinyl, 1,
- the “divalent heterocyclic group optionally having a substituent” means a divalent group having a bond at an arbitrary position of the “heterocyclic group”.
- the position of the bond is not particularly limited, and can be appropriately selected depending on the type of group.
- the “divalent heterocyclic group” include pyrrolyl, chenyl, furyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxa'zolyl, 1, 2, 4-oxadiazolyl, 1, 3, 4-oxadiazolyl 1, 2, 4-triazolyl, 1, 2, 4 1 thiadiazolyl, 1, 3, 4-thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, partially hydrogenated pyridazinyl, partially hydrogenated Optionally indenothiazolyl, partially hydrogenated naphthothiazolyl, quinazolyl, chromenyl, partially hydrogenated thiazolopyridyl, benzozepiel, thienopyridyl, benzothiazolyl, imidazolyl, tetrazolyl More preferred examples include chenil, thia Examples include zolyl, 1,3,4-thiadiazoly
- the type and number are particularly limited There is no particular definition, and it contains 1 to 3 substituents selected from the “substituent” forces defined below at substitutable positions.
- the substituent that the divalent heterocyclic group may have include C alkyl, haloalkyl, —6 alkoxy, hydroxy, halogen atom, oxo, thixo and the like, and more preferable examples are Examples thereof include methyl and oxo, and oxo is more preferred.
- C 3 _ 8 cycloalk Killen" of the "optionally substituted C 3 _ 8 cycloalkylene” is a monocyclic - tricyclic cycloalkylene ( "cross-linking of 3-8 carbon atoms Including, for example, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, cyclooctylene, norporylene, bicyclo [2.2.1] heptylene or bicyclo [2 2.2] octylene and the like are preferable, and cyclopropylene, cyclobutylene, cyclopentylene, and cyclohexylene are preferable.
- C 3 8 cycloalkylene has “substituent” are not particularly limited to the type and number, a substituent selected from the “substituents” defined below at its substitutable position It has 1 to 4 pieces.
- C 3 _ 8 C i- e alkyl Preferable examples of the cycloalkylene good location substituent optionally having, alkoxy, hydroxy, Amino, halogen atom, C - 6 haloalkyl, - be mentioned 6 haloalkoxy etc. In monkey.
- dialkyl in “optionally substituted alkyl” means straight or branched alkyl having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, tertiary pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, hexyl , Isohexyl, 1-Methylpentyl, 2-Methylpentyl, 3-Methylpentyl, 1,1-Dimethylptyl, 1,2-Dimethylptyl, 2,2-Dimethyloleptyl Z-re, 1-Echi / Leptinore, 1, 1 , 2-trimethylenopropynole, 1,2,2-trimethyleno
- C 6 -6 alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isoptyl and the like, and more preferable examples include methyl, ethyl and the like.
- R 2 and R 3 may be the same or different and each represents a hydrogen atom or alkyl. Alternatively, R 2 and R 3 together.
- the ring to which they are bonded may form a ring, and the ring which may have a substituent formed by R 2 and R 3 together with the atom to which they are bonded in “Ring” includes “nitrogen-containing saturated heterocycle” (for example, 1,3-imidazolidin-2-one, 3, 4,5,6-tetrahydro-2- ( 1 H) —pyrimidinone, etc.).
- the type and number thereof are not particularly limited, and 1 to 3 substituents selected from the “substituent” defined below can be substituted at the substitutable position. contains.
- substituents that the “ring” may have include 6 alkyl, alkoxy, hydroxy, halogen atom and the like.
- “0 ⁇ 6 alkylene” in “C i—e alkylene which may have a substituent” means an alkylene chain having 1 to 6 carbon atoms, such as methylene, ethylene, trimethylene, tetramethylene, Examples include pentamethylene and hexamethylene.
- Preferable examples of “C alkylene” include methylene, ethylene, and trimethylene, and more preferable examples include methylene and ethylene.
- a branched alkylene chain eg, methylmethylene, dimethylmethylene, 1 monomethylethylene, 2-methylenoethylene, 1 , 1-Dimethylethylene, 2,2-Dimethylenoethylene, Ethenolemethylene, Getinolemethylene, 1-Ethenoreethylene, 2-Ethylethylene, 1-Methyltrimethylene, 1,1-dimethyltrimethylene, 2-Methyltrimethylene 2,2-dimethyltrimethylene, 3-methinotritrimethylene, 3,3-dimethylenotritrimethylene, 1-ethylene / retrimethylene, 2-ethinoretrimethylene, 3-ethyltrimethylene, etc.).
- a branched alkylene chain eg, methylmethylene, dimethylmethylene, 1 monomethylethylene, 2-methylenoethylene, 1 , 1-Dimethylethylene, 2,2-Dimethylenoethylene, Ethenolemethylene, Getinolemethylene, 1-Ethenoreethylene, 2-Ethylethylene,
- Optionally substituted C 2 - 6 alkenylene and “C 2 _ 6 7 Luque two Len” includes straight-chain or branched having a double bond at any position of the "CI_ 6 alkylene” It is an alkyrene with 2 to 6 carbon atoms in the branch. The position and number of double bonds are not particularly limited.
- C 2 _ 6 alkylene has a “substituent” 5017002
- Kinds and numbers are not particularly limited, and have 1 to 3 substituents selected from the “substituents” defined below at substitutable positions.
- substituent which may be "C 2 - - 6 alkylene” optionally has can be mentioned alkyl, alkoxy, hydrate port alkoxy, a halogen atom.
- 0 may have a substituent group 3 - 8 cycloalkylidene” is a "C 3 _ 8 Shikuroa Rukiriden” on, is a monocyclic - tricyclic cycloalkylidene ( "cross-linking of 3-8 carbon atoms
- cyclopropylidene, cyclopropylidene, cyclopentylidene, cyclohexylidene, cycloheptylidene, cyclootatilidene, norbornylidene, bicyclo [2.2.1] heptylidene or Bicyclo [2.2.2] octylidene and the like are preferable, and cyclopropylidene, cyclobutylidene, cyclopentylidene, and cyclohexylidene are preferable.
- R 5 and R 6 may be the same or different and each represents a hydrogen atom or alkyl. Alternatively, R 5 and R 6 are the same. And the atoms to which they are bonded may form a ring.) "The ring that may have a substituent formed by R 5 and R 6 together with the atoms to which they are bonded”
- the term “ring” includes “nitrogen-containing saturated heterocycle” (for example, 1,3-imidazolidin-2-one, 3, 4, 5, 6-tetrahydro-2 (1H ) —Pyrimidinone).
- the type and number thereof are not particularly limited, and the “substituent” defined in the following is the power of the selected substituent. Contains. Preferable examples of the substituent that the “ring” may have — 6 alkyl, CI_ 6 alkoxy, human Dorokishi, and a halogen atom.
- C 3 - 8 cycloalkyl and "Ji 3 _ 8 cycloalkyl,” on, it is a monocyclic - tricyclic cycloalkyl ( "cross-linking of 3-8 carbon atoms Including, for example, cyclopropyl, cyclobutyl, cyclopentyl / le, cyclohexenole, cycloheptinole, cyclootatinole, nonoleponorinole, bicyclo [2.2.1] heptyl or bicyclo [ 2.2.2] Octyl and the like are preferable, and cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl / le are preferable.
- C 3 8 cycloalkyl When having - "C 3 8 cycloalkyl” force S "substituent", the kind ⁇ Pi number is not limited especially, the substitutable substituents selected from the “substituents" defined below 1 to 4 in effective positions.
- C -e alkyl as preferred examples of the C 3 _ 8 cycloalkyl substituent which may have. 6 Alkoxy, hydroxy, halogen atom, etc. can be mentioned.
- C _ 6 alkoxy in the "optionally C w alkoxy optionally having substituent” means alkoxy straight or branched chain containing from 1 to 6 carbon atoms, for example, main butoxy, ethoxy carboxylate, n-propoxy, isopropoxy, ⁇ -butoxy, isobutoxy, secondary butoxy, tertiary butoxy, pentoxy, isopentoxy, neopentoxy, tertiary pentoxy, 1-methylptoxy, 2-methylbutoxy, 1,2-dimethylpropoxy, 1 1-Methylpropoxy, Hexinoreoxy, Isohexyloxy, 1-Methylenopentoxy, 2-Methylenopentoxy, 3-Methylenopentoxy, 1,1-Dimethylptoxy, 1,2-Dimethylptoxy, 2 , 2-dimethylbutoxy, 1-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylenopropoxy, 1 Examples include chilled
- “6 alkoxy” include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and the like, and more preferable examples include methoxy, ethoxy and the like.
- C ⁇ 6 alkoxy has a substituent
- the type and number are not particularly limited.
- one to four “substituents” defined below may be present at substitutable positions, and the type and number of substituents are not particularly limited.
- Preferable examples of the substituent that “.-6 alkoxy” may have include C 6 alkyl, alkoxy, hydroxy, halogen atom and the like.
- “Mono or di C w alkylamino” in “optionally substituted mono or di C w alkylamino” means a linear or branched alkyl having 1 to 6 carbon atoms and mono. Or a di-substituted alkylamino (total number of carbon atoms in dialkylamino is 2 to 12) and is methylamino, dimethylamino, ethylamino, jetamino, methylethylamino, propylamino, dipropylamino, isopropylamino, diisopropylamino Ptylamino, dibutylamino, isopeptylamino, secondary butylamino, tertiary ptylamino, pentylamino, hexylamino and the like.
- Mechinoreamino Echireamino, Jechi / Reamino, Mechinoreechi ⁇
- Amino, Puropinore Amino, Jipuropiruamino, isopropyl ⁇ amino, diisopropylamino and the like elevation Gerare more preferred examples Examples thereof include methylamino, dimethylamino, ethylamino, jetylamino, methylethylamino, propylamino and the like.
- Ci acilamino in “optionally substituted Ci acilamino” means an alkanoyl having 1 to 7 carbon atoms in the acyl moiety (eg, formyl, acetyl, propiol, pentylyl, parrelyl).
- An alkylamine having 3 to 7 carbon atoms for example, acryloyl, methacryloyl, crotonol
- an alkynol having 3 to 7 carbon atoms for example, propioroyl
- benzoyl etc. Acetylamino, propionylamino, petitrilamino, Parerylamino, bivalloamino, benzoylamino and the like are shown.
- 0 ⁇ 7 acylamino include acetylamino, propionylamino, petitlylamino, pareillyamino, piperoylamino, benzoylamino and the like, and more preferable examples include acetylamino, propionylamino, benzoylamino and the like.
- “Diacylamino” force S When having a “substituent”, the type and number thereof are not particularly limited, and one substituent selected from the “substituent” defined below can be substituted at one of the substitutable positions. Have four.
- the ⁇ 7 Ashiruamino of the substituent which may have good case in point may be mentioned C 6 alkyl, alkoxy, hydroxy, halogen atom and the like.
- sulfonylamino In the case of having an “optionally substituted sulfonylamino” force “substituent”, the type and number thereof are not particularly limited, and a substituent selected from the “substituent” defined below is used. It has an amino group. Preferable examples of the substituent that sulfonylamino may have include amino, C- 6 alkyl, aryl, heteroaryl and the like.
- hydrazino When “optionally substituted hydrazino” has “substituent”, there is no particular limitation on the type and number of the substituent, and a substituent selected from the “substituent” defined below is used. There are 1 to 3 at the substitutable positions.
- substituent that hydrazino may have include Ci 6 alkyl, aryl, heteroaryl and the like. Examples of aryl and hetero reels are as described above.
- guanidino When “optionally substituted guanidino” has “substituent”, the type and number thereof are not particularly limited, and a substituent selected from “substituent” defined below is used. There are 1 to 3 at the substitutable positions. Preferable examples of the substituent that guanidino may have include hydroxy, nitro, and cyano.
- “Amidino which may have a substituent” force When “substituent” is present, the type and number thereof are not particularly limited, and the substituent selected from the “substituent” defined below is substituted. 1 to 3 in possible positions. Substituent which amidino may have Preferred examples of are hydroxy, nitro, cyan and the like.
- each group that may have a substituent is not particularly limited.
- a halogen atom eg, fluorine atom, chlorine atom, bromine atom, iodine atom
- C- 6 alkyl Formula example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, isopentinole, neopentinole, tertiary pentyl, 1-methylbutyl, 2-methylpropyl, 1,2-dimethylpropyl, 1-ethylpropyl, hexyl, isohexyl,
- a halogen atom eg, fluorine atom, chlorine atom, bromine atom, iodine atom
- C- 6 alkyl Formula example, methyl, ethyl, n-propyl, isopropyl, n-buty
- heptyl or bicyclo [2.2. 2] Okuchiru etc. C 3 - 8 cycloalkyl O alkoxy (e.g., Shikuropu port Piruokishi, cycloalkyl Petit Ruo alkoxy, cyclopentyloxy Ruo alkoxy, Kishiruo carboxymethyl cyclohexane, consequent opening Ptyloxy, cyclooctyloxy, norbornyloxy, bicyclo [2.2.1] heptyloxy or bicyclo [2.2.2] octyloxy, etc.), haloalkyl (for example, the above halogen such as trifluoromethyl)
- 6 alkoxy eg, methoxy, ethoxy, n-propoxy, isopropoxy, n-ptoxy, isobutoxy, secondary butoxy, tertiary butoxy, pentoxy, isopentoxy Neopentoxy
- Aarukanoiru e.g., Akuriroiru, methacryloyl, Kurotonoiru etc.
- C 3 _ 7 Arukinoiru e.g., propionate port I
- C 7 — aroyl e.g, benzoyl, 1-naphthoyl, 2_naphthyl, etc.
- mono or di (d-uT syl) amino eg, acetylylamino, benzoylamino, etc.) amino
- mono- or di one (E _ 6 alkoxy one carbonyl) amino e.g., main Tokishikarubo - Ruamino, eth Kishikarubo - Ru
- ring A represents an aryl which may have a substituent, or a heteroaryl which may have a substituent, and preferably a phenol which may have a substituent. It is.
- substituent for ring A examples include a halogen atom (for example, a fluorine atom, a chlorine atom, etc., particularly a chlorine atom), and Ci- 6 alkyl which may have a substituent (for example, substituted with a halogen atom).
- a halogen atom for example, a fluorine atom, a chlorine atom, etc., particularly a chlorine atom
- Ci- 6 alkyl which may have a substituent (for example, substituted with a halogen atom).
- which may be C i-6 alkyl, especially methyl, triflusulfuron Ruo b methyl) or optionally substituted C i _ 6 alkoxy (e.g., alkoxy substituted by halogen atoms, in particular methoxy) and the like Is preferred.
- Ring A is particularly preferably phenyl substituted with 1 or 2 fluorine atoms or chlorine atoms, more preferably phenyl substituted at the 3-position and Z- or 4-position with fluorine atoms or chlorine atoms, more preferably 3,4-dichlorophenyl or 3,4-difunoleorofeni / re.
- Ring B may have a substituent group Ariren may have a substituent divalent to heterocyclic group, an optionally C 3 _ 8 cycloalkylene which may have a substituent, Preferred is an arylene which may have a substituent, or a heteroarylene which may have a substituent.
- Preferred examples of ring B include phenylene, chainylene, pyridylene, thiazolylene optionally substituted with methyl, 1,3,4-thiadiazolylene, optionally substituted with oxo, and partially hydrogenated.
- An even more preferred embodiment is thiazolylene. Further, another preferred embodiment is 1,3,4-thiadiazolylene. Yet another more preferable embodiment is pyridazinylene which may be substituted with oxo and may be partially hydrogenated. In addition, as the substituent of ring B, alkyl or oxo is preferable, and methyl is more preferable.
- n represents an integer of 0 to 2, preferably 0 or 2, and more preferably 0.
- n an integer of 1 to 5, preferably 1 to 3, and more preferably 1.
- R 2 and R 3 are And together with the atoms to which they are bonded, they may form a ring that may have a substituent, the same shall apply hereinafter.), Oxygen atoms, sulfur atoms, one SO—, —S0 2 —, one NR a S0 2 -, - S0 2 NR a - a 6 Aruke two lens, the substituent - may have a substituent CI- e alkylene, but it may also have a substituent group C 2 May C 2 - 6 Aruki two lens, one O- X a - (X a in the formula may have a substituent -.
- a bond 1 NH—, 1 NR 1 —, 1 CO—, 1 C0 2 —, 1 OCO—, 1 CONR a —, 1 NR a CO—, — NR 2 CONR 3 —, an oxygen atom, a sulfur atom, ⁇ SO—, 1 S0 2 —, 1 NR a S0 2 —, 1 S0 2 NR a —, optionally substituted C 2 — 6- anolekenylene, 1 CO— X a —, 1 X a — CO— , 1 CONR a — X a —, -X a — CONR a —, 1 NR a CO— X a —, 1 X a — NR a CO— or optionally substituted c 3 — 8 cycloalkylidene
- 1 CO— a CO—, 1 C0 2 —, 1 OCO— 1 CONR a —, 1 NR a CO—, —
- a bond, —CO—, one CONR a— , one NR a CO—, one CO—X a , one X a — CO—, one CONR a — X a —, —X a — CONR a —, - NR a CO - X a - or one X a - is NR a CO-.
- R 1 represents an alkyl which may have a substituent, and is preferably an alkyl;
- R 2 and R 3 may be the same or different and each has a hydrogen atom or a substituent;
- R a represents a hydrogen atom or an alkyl which may have a substituent, preferably a hydrogen atom or alkyl
- X a may have a substituent — 6 represents alkylene, preferably alkylene.
- Y represents a bond, 1 NH—, —NR 4 — (wherein R 4 represents 6 alkyl which may have a substituent. The same shall apply hereinafter.), 1 CO—, 1 CO 2 — , 1 OCO—, —C ONR b — (wherein Rb represents a hydrogen atom or d-6 alkyl optionally having a substituent. The same shall apply hereinafter.), 1 NR b CO—, 1 NR 5 CONR 6 — (wherein R 5 and R 6 may be the same or different and each has a hydrogen atom or a substituent. Also good Ci- 6 alkyl. Alternatively, R 5 and R 6 may be joined together to form an optionally substituted ring with the atoms to which they are attached.
- Oxygen atom, sulfur atom, —SO—, — S0 2 —, — NR b S0 2 —, —S0 2 NR b —, may have a substituent, alkylene, may have a substituent have good C 2 - 6 Aruke two alkylene which may have a substituent C 2 - 6 alkylene - alkylene, single O- X b _ (3 ⁇ 4 wherein ⁇ may have a substituent Ci- e represents alkylene, and so on.), — X b — O—, —CO— X b —, One X b — CO—, One CONR b — X b —, — X b — CONR b —, One NR b CO— X b —, 1 X b — NR b CO—, 1 S— X b —, 1 X b — S—, 1 SO— X
- a bond Preferably a bond, one NH—, — NR 4 —, one CO—, one C ⁇ 2 —, one OCO—, one CONR b —, one NR b CO—, — NR 5 CONR 6 —, an oxygen atom, a sulfur atom , 1 SO—, 1 S0 2 —, — NR b S0 2 —, 1 S0 2 NR b —, — CO— X b —, 1 X b — CO—, 1 CONR b — X b —, 1 X b— coNR b —, — NR b CO— X b — or — X b — NR b CO—;
- R 4 represents an optionally substituted C- 6 alkyl, preferably Ci- 3 alkyl
- R 5 and R 6 may be the same or different and each represents a hydrogen atom or 6- alkyl which may have a substituent, preferably a hydrogen atom
- R b may have a hydrogen atom or a substituent It indicates Kill, preferably hydrogen atom or an 0 3 alkyl
- x b is, C] optionally have a substituent - 6 an alkylene, preferably a C i-3 alkylene.
- Z represents a hydrogen atom, a halogen atom, an alkyl which may have a substituent, which may have a substituent group c 3 _ 8 cycloalkyl, optionally ⁇ reel may have a substituent, the substituent Heterocyclic group optionally having hydroxy, nitro, amino, cyano, optionally having alkoxy, optionally having mono- or di-6-alkylamino, substituent C-7 acylamino, optionally substituted sulfonylamino, optionally substituted hydrazino, optionally substituted guanidino Or amidino optionally having substituents;
- a hydrogen atom More preferably, a hydrogen atom, a hydroxy, an amino, an optionally substituted 6 alkyl, an optionally substituted — 6 alkoxy, an optionally substituted aryl or a substituted group It is a heterocyclic group which may have.
- Even more preferred is a hydrogen atom, hydroxy or amino, and even more preferred is hydroxy or amino. An even more preferred embodiment is hydroxy. An even more preferred embodiment is amino.
- Preferable examples of the group represented by Z—Y—X— include a hydrogen atom, carboxyl, carboxymethyl, amino, carbamoyl, carbamoylmethyl, (2-amino-2-oxoethyl) aminocarbonyl and the like.
- the compound represented by the general formula (1) includes the general formula (la)
- ring C represents aryl or heteroaryl which may have a substituent, and other symbols are as defined above.
- ring C is preferably phenyl, pyridyl, partially hydrogenated 1, 2, 4-oxadiazolyl, 1, 2, 4_triazolyl, tetrazolyl, isoxazolyl, etc. is there.
- Ci-e alkyl, —6 alkoxy, hydroxy, nitro, amino, cyan, forceful loxy, Ci- 6 alkoxy forceful lponyl, force lupamoyl, oxo and the like are preferable, and methoxy, Hydroxy, amino, carboxy, methyl, carbamoyl and oxo are more preferred.
- the compound of the general formula (1) and pharmaceutically acceptable salts thereof may exist in the form of hydrates or solvates (for example, ethanol solvates). Therefore, these hydrates, solvates Also included in the present invention. Further, since the compound of the general formula (1) has an asymmetric atom, at least two kinds of optical isomers exist. These optical isomers and their racemates are included in the present invention.
- the compound of the general formula (1) is prepared by the following methods (1) to (11) and methods according to these methods, methods known to those skilled in the art of organic synthesis, and WO 97/24325, WO 98/25617. , WO 98/02151, WO 98/04554, WO 00 no 34278, WO 99 no 55324, WO 99/55330, WO 00/58 305, WO 00/31033, WO 00/53600, WO 01/14333, WO02 / 66460 , WO 02/881 1 1, WO 02/18335, WO 0 229 5, WO 03/82863, WO 03/99287, WO 03/99798 (these documents are incorporated herein by reference) and can be synthesized by a method according to the method described in, etc. .
- heteroaryl (including heteroarylene) necessary substituents used in the description of the synthesis method below means an addition reaction or water, alcohol, acid in many cases by an acid or base catalyst, light, heat, etc. It means a substituent necessary for constructing a heteroaryl by a condensation reaction accompanied by elimination of hydrogen halide or the like.
- Specific examples of the “substituents necessary for the construction of heteroaryl” include one of a combination of promoacetyl and thioamide in the construction of thiazole, and a combination of hydroxyamidine and carboxylic acid in the construction of 1, 2, 4-oxadiazole.
- under ice cooling or at room temperature means 0 to 30 ° C.
- an appropriate solvent that does not inhibit the reaction for example, tetrahydrofuran (hereinafter abbreviated as THF), dichloromethane, ⁇ , ⁇ -dimethylformamide (hereinafter abbreviated as DMF) or any mixed solvent thereof, etc., in the presence of a tertiary amine such as triethylamine, diisopropylethylamine, etc., in the presence of a condensing agent [e.g.
- DCC ⁇ - (3-Dimethylaminopropyl)- ⁇
- EDC monoethyl carpositimide
- EDQ 2-ethoxy-1 1-ethoxycarboyl 1,2-Dihydroxyquinoline
- CD I Carposiimidazole
- PyBOP Jetyl phosphoryl cyanide Benzotriazole 1-yloxytrispyrrolidinophosphohexahexenoreophosphate
- DPPA diphenylphosphoryl azide
- isobutyl chloroformate jetylacetyl chloride, trimethyl chloride A cetyl etc.
- the compound represented by the general formula (1) can be obtained by reacting the compound represented by the general formula (2) as a reactive derivative (for example, acid chloride, acylimidazole, etc.).
- a reactive derivative for example, acid chloride, acylimidazole, etc.
- this reaction is carried out in the presence of a tertiary amine such as triethylamine or pyridine in an appropriate solvent that does not inhibit the reaction (eg THF, dichloromethane, chloroform, benzene, or any mixed solvent thereof). Perform for 1 to 24 hours under ice cooling or at room temperature.
- a tertiary amine such as triethylamine or pyridine
- an appropriate solvent that does not inhibit the reaction
- G 1 represents a protecting group (for example, tert-ptoxycarbonyl (B oc), benzyloxycarbol (Cb z))). Or a tertiary amine such as triethylamine or diisopropylethylamine in an appropriate solvent that does not inhibit the reaction (THF, dichloromethane, DMF, or any mixed solvent thereof).
- a condensing agent synthetic with the condensing agent described in Method (1)
- each symbol is the same as described above.
- the protecting group is a Boc group in this compound, for example, hydrogen chloride or trifluoroacetic acid (hereinafter abbreviated as TFA) in an inert solvent such as acetonitrile, THF, 1,4-dioxane, ethyl acetate or the like. Deprotection is usually performed using acid at 30-60 ° C for 10 minutes-24 hours.
- the protecting group is a Cb Z group, for example, in an inert solvent such as methanol, ethanol, ethyl acetate, etc.
- a catalyst such as palladium on carbon, deprotection is carried out by reaction at ⁇ 30 to 60 ° C. for 10 minutes to 24 hours using an acid such as catalytic reduction with hydrogen or hydrogen bromide monoacetic acid.
- This compound is represented by the general formula (7)
- L 1 represents a leaving group such as chlorine, bromine, iodine, methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfuroxy, etc., and other symbols are the same as above.
- a suitable solvent that does not inhibit the reaction THF, dichloromethane, DMF, or any mixed solvent thereof
- X represents one CONH— (CH 2 ) q — (wherein q represents an integer from 0 to 6). Is obtained.
- the compound represented by the general formula (1) can be obtained by reacting the compound of the general formula (9) as a reactive derivative (acid chloride, acyl imidazole, etc.) in the same manner.
- X represents one NHCO— (CH 2 ) q ⁇ (wherein q represents an integer of 0 to 6). Is obtained.
- the compound represented by the general formula (1) can be obtained by reacting the compound of the general formula (12) as a reactive derivative (acid chloride, acyl imidazole, etc.) in the same manner.
- L 2 represents a leaving group such as chlorine, bromine, iodine, methanesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy, etc., and other symbols are as defined above.
- an acid addition salt thereof in the presence of a base such as triethylamine, pyridine, DMAP, potassium carbonate, sodium bicarbonate, sodium hydroxide, or the like, in an ice-cooled state or at room temperature for 1 to 24 hours.
- a base such as triethylamine, pyridine, DMAP, potassium carbonate, sodium bicarbonate, sodium hydroxide, or the like
- n 1, and is an optically active substance.
- the compound represented by the above or an acid addition salt thereof is converted into an appropriate solvent that does not inhibit the reaction (eg, dichloromethane, chloroform, dichloroethane, acetic acid, or any of these). In a mixed solvent, etc.), it is produced by reacting with a halogenating agent such as chlorine, bromine, pyridine tribromide, trimethylphenylammonium tribromide, iodine, etc. at 0-100 ° C for 10 minutes to 24 hours. Can do.
- the compound represented by the general formula (26) or an acid addition salt thereof is a novel compound and can be produced by converting the optically active form of the compound represented by the above general formula (3) into acetylene by a conventional method. it can.
- L 3 represents a leaving group such as chlorine, bromine, iodine, methanesulfo-loxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy, etc., and other symbols are as defined above.
- an acid addition salt thereof in a suitable solvent that does not inhibit the reaction for example, dichloromethane, chloroform, dichloroethane, jetyl ether, dimethylformamide, water, or any mixed solvent thereof.
- an appropriate solvent that does not inhibit the reaction for example, halogenated hydrocarbons such as dichloromethane, dichloroethane, black mouth form, etc.
- an oxidizing agent such as tachloroperbenzoic acid, or an oxidizing agent such as hydrogen peroxide in a carboxylic acid solvent such as acetic acid, trifluoroacetic acid, formic acid, etc.
- the substituent when an amino group or the like that does not participate in the reaction is present in the reactant, the substituent is protected with an appropriate protecting group, and then the reaction is carried out, and the protecting group can be removed after the reaction.
- Protecting groups for the amino group used in this case include tertiary butoxycarbonyl, carpamates such as benzyloxycarbonyl, amides such as formyl, acetyl, trifnoreoloacetylinole, benzoinole, benzinole, p- And arylalkyl such as methoxybenzyl and trityl.
- These protecting groups can be removed by, for example, solvolysis using an acid such as hydrochloric acid, formic acid or trifluoroacetic acid, or a base such as sodium hydroxide or potassium hydroxide, or reduction using a metal hydride complex
- the palladium-carbon catalyst can be obtained by catalytic reduction using Raney nickel or the like, or oxidation using 2,3-dichloro-1,5,6-dichloro-1, p-benzoquinone or the like.
- ring B represents heteroarylene which may have a substituent, and other symbols are as defined above.
- Z represents an optionally substituted heteroaryl, and the other symbols are the same as those described above. It is synonymous with. ) Is obtained.
- X is —Qi— (CH 2 ) q — [wherein is one NH—, —NR 7 — (wherein R 7 may have a substituent — 6 alkyl ) Represents an oxygen atom or a sulfur atom, and q represents an integer of 0 to 6. ], It can also be synthesized by the following method.
- G 6 represents one NH 2 , —NHR 7 (wherein R 7 represents an optionally substituted substituent_ 6 alkyl), one OH or one SH, The symbols are as defined above. ] Or a suitable solvent that does not inhibit the reaction.
- L 4 represents a leaving group such as chlorine, bromine, iodine, methanesulfo-loxy, p-toluenesulfonyl / leoxy, trifluoromethanesulfo-oxy, and other symbols are as defined above.
- X is — Q 2 — (CH 2 ) q — (wherein Q 2 is 1 NH—, 1 NR 7 — (wherein R 7 may have a substituent) — Represents 6 alkyl)) represents an oxygen atom or sulfur atom, and q represents an integer of 0 to 6. In the case of), it can also be synthesized by the following method.
- L 5 represents a leaving group such as chlorine, bromine, iodine, methanesulfonyloxy, ⁇ -toluenesulfonyloxy, trifluoromethanesulfonyloxy, etc., and other symbols are as defined above.
- an acid addition salt thereof in an appropriate solvent that does not inhibit the reaction for example, dichloromethane, chloroform, dichloroethane, jetyl ether, water, or any mixed solvent thereof).
- G 7 one NH 2, (In the formula, R 7 is a good 0 E _ 6 alkyl which may have a substituent.) -NHR 7, one OH or - indicates SH, the other The symbols are as defined above. Or the acid addition salt thereof in the presence of a base such as triethylamine, pyridine, DMAP, potassium carbonate, sodium bicarbonate, sodium hydroxide, or the like, in an ice bath or at room temperature for 1 to 24 hours.
- a base such as triethylamine, pyridine, DMAP, potassium carbonate, sodium bicarbonate, sodium hydroxide, or the like
- Examples of the pharmaceutically acceptable salt of the compound of the general formula (1) include acid addition salts with inorganic acids or organic acids, and the compound of the general formula (1) is treated with an inorganic acid or an organic acid by a conventional method. To obtain a salt. Further, hydrates and solvates of the compound of the general formula (1) are also included in the present invention and can be produced by a known method.
- the compound of the present invention thus obtained can be isolated and purified by a conventional method such as recrystallization or column chromatography.
- a conventional method such as recrystallization or column chromatography.
- the resulting product is a racemate, it can be resolved into the desired optically active substance, for example, by fractional recrystallization of a salt with an optically active acid, or by passing through a power ram filled with an optically active carrier. Can do.
- Individual diastereomers can be separated by means of fractional crystallization, column chromatography and the like. These can also be obtained by using optically active raw material compounds.
- Stereoisomers can be isolated by recrystallization, column chromatography, or the like.
- a carrier for example, an excipient, a binder
- a disintegrant, etc. can be administered orally or parenterally in the form of a pharmaceutical composition obtained by mixing with a disintegrant, etc. or a preparation (eg, tablet, liquid, etc.).
- the pharmaceutical composition can be formulated according to a usual method.
- Dosage depends on age, weight, general health, sex, diet, time of administration, method of administration, excretion rate, combination of drugs, and the patient's current condition, or other factors Determined in consideration of
- the daily dose of the compound of the present invention varies depending on the patient's condition and body weight, the type of compound, the route of administration, etc. For example, orally, the dose is 0.01 to 100 mg / kg body weight per day. Yes, it is administered once to several times a day, and parenterally, about 0.0 1 to 10 O mg Z kg body weight is administered one to several times a day. preferable.
- Diseases that can be treated or prevented include, for example, diseases in which cells with CCR 3 play an important role in the pathogenesis, progression, and maintenance of diseases, such as asthma, sinusitis, allergy Rhinitis, atopic dermatitis, allergic conjunctivitis, Examples include allergic myelitis, ulcerative colitis, Crohn's disease, and rheumatoid arthritis.
- the treatment in the present invention is intended to cure a disease, reduce a disease, prevent a disease from worsening, or prevent a seizure in an individual who has already developed a disease (for example, a mammal including a human).
- prevention means that the compound of the present invention is administered to a healthy individual who has not developed the disease (for example, mammals including humans) for the purpose of preventing the onset of the disease. Means.
- the 1 H-NMR spectrum of the compound was measured at 30 OMHz or 40 OMHz.
- TMS tetramethylsilane
- ⁇ relative delta
- Coupling constants indicate trivial multiplicity in hertz (Hz), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet-of-doublets) , Brs (broad singlet), etc.
- Column chromatography was performed using silica gel manufactured by Fuji Silicon Chemical Co., Ltd. Separation by HP LC was carried out using a column made by WATERS or Shiseido, using a mixed solvent of 0.05% TFA aqueous solution and 0.05% TFA-acetonitrile solution as the eluent.
- room temperature used in the description of the following examples means 10 to 30 ° C.
- the title compound 65 Omg was obtained as a slightly yellow amorphous solid from 422 mg of the product of (1-1) and 302 mg of the product of (5-1) by the same method as (1-4).
- the obtained residue was purified by silica gel column chromatography using a mixed solvent of black mouth form and ethanol as an eluent. The solvent was distilled off from the eluate to give 202 mg of the title compound as a white amorphous solid.
- the obtained residue was purified by silica gel column chromatography using a mixed solvent of black mouth form and methanol as an eluent.
- the solvent was distilled off from the eluate to obtain 3.87 g of the title compound as a slightly yellow amorphous solid.
- Example 9 To a solution of 262 mg of pyridine in 2 mL, 5 7 L of acetic anhydride was added dropwise. The reaction was stirred overnight at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography using a mixed solvent of chloroform and methanol as an eluent. The solvent was removed from the eluate to obtain 279 tng of the title compound as a white amorphous solid.
- the obtained residue was purified by silica gel column chromatography using a mixed solvent of chloroform and methanol as an eluent. The solvent was distilled off from the eluate to obtain 44 lmg of the title compound free form as a slightly yellow amorphous solid. From the obtained residue, the title compound (357 mg) was obtained as slightly yellow crystals by the same method as in (1-2).
- the product 490111 ⁇ of (22-2) was dissolved in xylene 61111 ⁇ and pyridine 1111. After 104 L of acetic anhydride was added dropwise, the mixture was heated to reflux for 2 hours. After allowing to cool, 28 L of acetic anhydride was added dropwise, and the mixture was further heated to reflux for 4 hours. Ethyl acetate was added to the reaction solution, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography using a mixed solvent of black mouth form and methanol as an eluent. The solvent was removed from the eluate to give the title compound-free compound 45 7 mg as a pale yellow oil. From the obtained residue, 75 mg of the title compound 2 was obtained as white crystals by the same method as (1 1 2).
- the title compound 5 2 Omg was obtained as a pale yellow powder from 500 mg of the product of (2 6-1) and 700 mg of the product of (1-1) by the same method as in (1 -4).
- the title compound 5 7 Omg was obtained as a white amorphous solid from 60 mg of the product (28-2) by the same method as in Example 9.
- Example 3 Product of 1 50 Omg and 4 monopyridylboronic acid 25 Omg were dissolved in a mixed solvent of ethylene glycol dimethyl ether 25 niL and water 5 ml, sodium hydrogen carbonate 500 mg and tetrakistriethanol ⁇ phosphine palladium 6 Omg was added and stirred at 100 ° C overnight.
- the reaction mixture was poured into water and extracted with ethyl acetate.
- the extract was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
- the obtained residue was purified by silica gel column chromatography using a mixed solvent of black mouth form and methanol as an eluent. The solvent was distilled off from the eluate, and the obtained residue was recrystallized with ethyl acetate to give the title compound 9 Omg as a pale brown powder.
- Example 33 The product of Example 33 was obtained in the same manner as in Example 9 and 300 mg of the title compound as a white powder.
- the title compound (592 mg) was obtained as a white amorphous solid by the same method as in Example 16 using 476 mg of the product of (1-5) and 20 lmg of glycine mono-tert-butyl ester hydrochloride.
- the title compound trifluoroacetate was obtained as a colorless oil from 2 mg of the product (4 6-1) in the same manner as in (4 2-2). From the residue obtained (1 1 2) In the same manner, 531 mg of the title compound was obtained as a white powder.
- the title compound trifluoroacetate was obtained as a colorless oil from 56 lmg of the product of Example 47 by a method similar to (42-2). From the obtained residue, 49 lmg of the title compound was obtained as a white powder by the same method as (1 1-2).
- the title compound-free product was obtained as a colorless oil from 500 mg of the product (50-1) by the same method as (1-5). From the obtained residue, the title compound (470 mg) was obtained as a white powder in the same manner as in (1-2).
- the title compound 6 7 7 mg was obtained as a pale yellow oil from 476 mg of the product of (1-5) and L-alanin benzyl ester tosylate 4 • 22 mg in the same manner as in Example 16.
- the title compound-free product was obtained as a colorless oil from 6 7 7 mg of the product (5 1-1) in the same manner as in (1-5).
- the title compound 4 8 Omg was obtained as a white powder from the obtained residue by the same method as in (1-2).
- the reaction was performed from 975 mg of the product of (54-2) by the same method as in (1-5), and purification was performed by HP LC to obtain the trifluoroacetate salt of the title compound as a colorless oil.
- the title compound 12 Omg was obtained as a white solid from the obtained residue by the same method as (1 1 2).
- the title compound 1.31 g was obtained as a white amorphous solid from 1.34 g of the product of (55-3) by the same method as (1-5).
- the title compound 1 8 3 mg was obtained as a white amorphous solid from the product 4 4 O mg of (6 8-2) by the same method as (1-5).
- the title compound 3 6 lmg was obtained as a white amorphous solid from 45 Omg of the product (72-1) by the same method as (70-2).
- the title compound 14 Omg was obtained as a pale yellow solid from 36 mg of the product 7-2) by the same method as (70-3).
- the title compound 4.40 g was obtained as a white amorphous solid from 3.96 g of the product of (75-3) by the same method as (1-2).
- the extract was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
- the resulting residue was purified by silica gel gel chromatography using a mixed solvent of black mouth form and acetone as an eluent. The solvent was distilled off from the eluate to obtain 830 mg of the title compound as a colorless oil.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3493CHN2014 IN2014CN03493A (US06903085-20050607-C00131.png) | 2004-09-08 | 2005-09-08 | |
EP05783689.2A EP1801108B9 (en) | 2004-09-08 | 2005-09-08 | Morpholine compounds for the treatment of inflammations |
ES05783689T ES2396419T3 (es) | 2004-09-08 | 2005-09-08 | Compuestos de morfolina para el tratamiento de inflamaciones |
US11/662,228 US7935700B2 (en) | 2004-09-08 | 2005-09-08 | Morpholine compound |
PL05783689T PL1801108T3 (pl) | 2004-09-08 | 2005-09-08 | Związki morfolinowe do leczenia stanów zapalnych |
JP2006535186A JP4970946B2 (ja) | 2004-09-08 | 2005-09-08 | モルホリン化合物 |
DK05783689.2T DK1801108T3 (da) | 2004-09-08 | 2005-09-08 | Morpholinforbindelser til behandling af inflammationer. |
CA2579207A CA2579207C (en) | 2004-09-08 | 2005-09-08 | Morpholine compound |
CN2005800301370A CN101014580B (zh) | 2004-09-08 | 2005-09-08 | 吗啉化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-261655 | 2004-09-08 | ||
JP2004261655 | 2004-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006028284A1 true WO2006028284A1 (ja) | 2006-03-16 |
Family
ID=36036551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017002 WO2006028284A1 (ja) | 2004-09-08 | 2005-09-08 | モルホリン化合物 |
Country Status (13)
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008007691A1 (fr) | 2006-07-11 | 2008-01-17 | Mitsubishi Tanabe Pharma Corporation | Sels de composé de morpholine |
WO2008036642A3 (en) * | 2006-09-19 | 2008-08-07 | Incyte Corp | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008123582A1 (ja) | 2007-04-04 | 2008-10-16 | Kowa Company, Ltd. | テトラヒドロイソキノリン化合物 |
JP2010504347A (ja) * | 2006-09-19 | 2010-02-12 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル |
US8034953B2 (en) | 2005-05-10 | 2011-10-11 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8796319B2 (en) | 2008-07-08 | 2014-08-05 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
WO2015012332A1 (ja) * | 2013-07-24 | 2015-01-29 | 田辺三菱製薬株式会社 | 眼科疾患治療剤 |
US9321755B2 (en) | 2013-11-08 | 2016-04-26 | Incyte Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
WO2020203822A1 (ja) * | 2019-03-29 | 2020-10-08 | 千寿製薬株式会社 | 血管新生を伴う網膜疾患の治療又は予防のための併用医薬 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE398616T1 (de) * | 2005-02-04 | 2008-07-15 | Ctg Pharma S R L | Neue 4-aminochinolinderivate als antimalariamittel |
US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US20220280487A1 (en) * | 2019-08-26 | 2022-09-08 | Stichting Vumc | Inhibition of mycobacterial type vii secretion |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0243959A1 (en) | 1986-04-30 | 1987-11-04 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same |
JPS63264467A (ja) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
WO1998002151A2 (en) | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO1998004554A1 (fr) | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Antagonistes de recepteurs de chemokines |
WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
WO1999055324A1 (en) | 1998-04-27 | 1999-11-04 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO1999055330A1 (en) | 1998-04-27 | 1999-11-04 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000031033A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
WO2000034278A1 (fr) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif |
WO2000053600A1 (fr) | 1999-03-11 | 2000-09-14 | Banyu Pharmaceutical Co., Ltd. | Derives piperidiniques |
WO2000058305A1 (en) | 1999-03-26 | 2000-10-05 | Astrazeneca Ab | Novel compounds |
WO2001014333A1 (en) | 1999-08-24 | 2001-03-01 | Astrazeneca Uk Limited | Substituted piperidine compounds useful as modulators of chemokine receptor activity |
WO2002018335A1 (fr) | 2000-08-28 | 2002-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amine cyclique |
WO2002026723A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Compounds useful in the treatment of inflammatory diseases |
WO2002026722A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
WO2002066460A1 (en) | 2001-02-19 | 2002-08-29 | Astrazeneca Ab | Chemical compounds |
WO2002088111A1 (fr) | 2001-04-27 | 2002-11-07 | Mitsubishi Pharma Corporation | Nouveaux composes de benzylpiperidine |
WO2003082863A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases |
WO2003082295A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholine derivatives substituted at the 2-position by a heterocyclylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions |
WO2003082294A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholine derivatives with a substituted acetamide group in the 2-position for use as ccr-3 antagonists for the treatment of inflammatory diseases |
WO2003082862A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Anti-inflammatory morpholin-acetamide derivatives |
WO2003082861A2 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases |
WO2003082292A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholine derivatives substituted at the 2-position by an arylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions |
WO2003099287A1 (en) | 2002-05-29 | 2003-12-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
WO2003099798A1 (en) | 2002-05-29 | 2003-12-04 | Glaxo Group Limited | Morpholinylmethylureas ccr-3 receptor antagonist |
WO2004004731A1 (en) * | 2002-07-02 | 2004-01-15 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03148276A (ja) * | 1989-11-01 | 1991-06-25 | Yoshitomi Pharmaceut Ind Ltd | 光学活性なピリドンカルボン酸化合物 |
-
2005
- 2005-09-08 ES ES05783689T patent/ES2396419T3/es active Active
- 2005-09-08 KR KR1020077007863A patent/KR101011848B1/ko active IP Right Grant
- 2005-09-08 EP EP05783689.2A patent/EP1801108B9/en active Active
- 2005-09-08 DK DK05783689.2T patent/DK1801108T3/da active
- 2005-09-08 IN IN3493CHN2014 patent/IN2014CN03493A/en unknown
- 2005-09-08 US US11/662,228 patent/US7935700B2/en not_active Expired - Fee Related
- 2005-09-08 JP JP2006535186A patent/JP4970946B2/ja not_active Expired - Fee Related
- 2005-09-08 PT PT57836892T patent/PT1801108E/pt unknown
- 2005-09-08 PL PL05783689T patent/PL1801108T3/pl unknown
- 2005-09-08 WO PCT/JP2005/017002 patent/WO2006028284A1/ja active Application Filing
- 2005-09-08 TW TW094130939A patent/TW200619212A/zh not_active IP Right Cessation
- 2005-09-08 CN CN2005800301370A patent/CN101014580B/zh not_active Expired - Fee Related
- 2005-09-08 CA CA2579207A patent/CA2579207C/en not_active Expired - Fee Related
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0243959A1 (en) | 1986-04-30 | 1987-11-04 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same |
JPS63264467A (ja) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
WO1998002151A2 (en) | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO1998004554A1 (fr) | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Antagonistes de recepteurs de chemokines |
WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
WO1999055324A1 (en) | 1998-04-27 | 1999-11-04 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO1999055330A1 (en) | 1998-04-27 | 1999-11-04 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000031033A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
WO2000034278A1 (fr) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif |
WO2000053600A1 (fr) | 1999-03-11 | 2000-09-14 | Banyu Pharmaceutical Co., Ltd. | Derives piperidiniques |
WO2000058305A1 (en) | 1999-03-26 | 2000-10-05 | Astrazeneca Ab | Novel compounds |
WO2001014333A1 (en) | 1999-08-24 | 2001-03-01 | Astrazeneca Uk Limited | Substituted piperidine compounds useful as modulators of chemokine receptor activity |
WO2002018335A1 (fr) | 2000-08-28 | 2002-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amine cyclique |
WO2002026723A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Compounds useful in the treatment of inflammatory diseases |
WO2002026722A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
JP2004509952A (ja) * | 2000-09-29 | 2004-04-02 | グラクソ グループ リミテッド | 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体 |
WO2002066460A1 (en) | 2001-02-19 | 2002-08-29 | Astrazeneca Ab | Chemical compounds |
WO2002088111A1 (fr) | 2001-04-27 | 2002-11-07 | Mitsubishi Pharma Corporation | Nouveaux composes de benzylpiperidine |
WO2003082862A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Anti-inflammatory morpholin-acetamide derivatives |
WO2003082294A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholine derivatives with a substituted acetamide group in the 2-position for use as ccr-3 antagonists for the treatment of inflammatory diseases |
WO2003082295A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholine derivatives substituted at the 2-position by a heterocyclylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions |
WO2003082861A2 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases |
WO2003082292A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | Morpholine derivatives substituted at the 2-position by an arylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions |
WO2003082863A1 (en) | 2002-03-28 | 2003-10-09 | Glaxo Group Limited | N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases |
WO2003099287A1 (en) | 2002-05-29 | 2003-12-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
WO2003099798A1 (en) | 2002-05-29 | 2003-12-04 | Glaxo Group Limited | Morpholinylmethylureas ccr-3 receptor antagonist |
WO2004004731A1 (en) * | 2002-07-02 | 2004-01-15 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
Non-Patent Citations (14)
Title |
---|
ARTHRITIS RHEUM., vol. 44, no. 5, 2001, pages 1022 - 1032 |
CELL TECHNOLOGY, vol. 17, 1998, pages 1022 - 1029 |
IMMUNITY, vol. 12, 2000, pages 121 - 127 |
J. CLIN. INVEST., vol. 100, no. 5, 1997, pages 1137 - 1143 |
J. CLIN. INVEST., vol. 109, no. 5, 2002, pages 621 - 628 |
J. CLIN. INVEST., vol. 99, no. 2, 1997, pages 178 - 184 |
J. EXP. MED., vol. 167, 1988, pages 1883 - 1893 |
J. EXP. MED., vol. 190, no. 2, 1999, pages 267 - 280 |
J. IMMUNOL., vol. 163, no. 3, 1999, pages 1545 - 1551 |
PHARMACOL. REV., vol. 52, no. 1, 2000, pages 145 - 176 |
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 9223 - 9237 |
SCIENCE, vol. 277, no. 5334, 1997, pages 2005 - 2007 |
See also references of EP1801108A4 |
SUGAWARA ET AL., ALLERGY & CLINICAL IMMUNOLOGY INTERNATIONAL, 2000, pages 785 |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034953B2 (en) | 2005-05-10 | 2011-10-11 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US10208002B2 (en) | 2005-05-10 | 2019-02-19 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US8846726B2 (en) | 2005-05-10 | 2014-09-30 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US11192868B2 (en) | 2005-05-10 | 2021-12-07 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
US8372870B2 (en) | 2005-05-10 | 2013-02-12 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer |
US8951536B2 (en) | 2005-12-20 | 2015-02-10 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
JP2014015489A (ja) * | 2006-07-11 | 2014-01-30 | Mitsubishi Tanabe Pharma Corp | モルホリン化合物の塩 |
EP2042499A4 (en) * | 2006-07-11 | 2009-10-21 | Mitsubishi Tanabe Pharma Corp | SALTS OF MORPHOLINE COMPOUND |
WO2008007691A1 (fr) | 2006-07-11 | 2008-01-17 | Mitsubishi Tanabe Pharma Corporation | Sels de composé de morpholine |
EP2042499A1 (en) * | 2006-07-11 | 2009-04-01 | Mitsubishi Tanabe Pharma Corporation | Salt of morpholine compound |
US8030303B2 (en) | 2006-07-11 | 2011-10-04 | Mitsubishi Tanabe Pharma Corporation | Salt of morpholine compound |
JP5501615B2 (ja) * | 2006-07-11 | 2014-05-28 | 田辺三菱製薬株式会社 | モルホリン化合物の塩 |
TWI399375B (zh) * | 2006-07-11 | 2013-06-21 | Mitsubishi Tanabe Pharma Corp | 嗎啉化合物之鹽 |
US8377976B2 (en) | 2006-09-19 | 2013-02-19 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8507541B2 (en) | 2006-09-19 | 2013-08-13 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
JP2010504347A (ja) * | 2006-09-19 | 2010-02-12 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル |
JP2010504346A (ja) * | 2006-09-19 | 2010-02-12 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロサイクル |
WO2008036642A3 (en) * | 2006-09-19 | 2008-08-07 | Incyte Corp | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US8273766B2 (en) | 2007-04-04 | 2012-09-25 | Kowa Company, Ltd. | Tetrahydroisoquinoline compound |
WO2008123582A1 (ja) | 2007-04-04 | 2008-10-16 | Kowa Company, Ltd. | テトラヒドロイソキノリン化合物 |
US8822511B2 (en) | 2008-07-08 | 2014-09-02 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US10369137B2 (en) | 2008-07-08 | 2019-08-06 | Incyte Corporation | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US9320732B2 (en) | 2008-07-08 | 2016-04-26 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US11207302B2 (en) | 2008-07-08 | 2021-12-28 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US8993605B2 (en) | 2008-07-08 | 2015-03-31 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US9789094B2 (en) | 2008-07-08 | 2017-10-17 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US8796319B2 (en) | 2008-07-08 | 2014-08-05 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US10034864B2 (en) | 2008-07-08 | 2018-07-31 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
US10653677B2 (en) | 2008-07-08 | 2020-05-19 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
JPWO2015012332A1 (ja) * | 2013-07-24 | 2017-03-02 | 田辺三菱製薬株式会社 | 眼科疾患治療剤 |
WO2015012332A1 (ja) * | 2013-07-24 | 2015-01-29 | 田辺三菱製薬株式会社 | 眼科疾患治療剤 |
US10130634B2 (en) | 2013-07-24 | 2018-11-20 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for ophthalmic disease |
US10280157B2 (en) | 2013-11-08 | 2019-05-07 | Incyte Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
US9873688B2 (en) | 2013-11-08 | 2018-01-23 | Incyte Holdings Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
US9321755B2 (en) | 2013-11-08 | 2016-04-26 | Incyte Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
WO2020203822A1 (ja) * | 2019-03-29 | 2020-10-08 | 千寿製薬株式会社 | 血管新生を伴う網膜疾患の治療又は予防のための併用医薬 |
Also Published As
Publication number | Publication date |
---|---|
ES2396419T3 (es) | 2013-02-21 |
KR20070099528A (ko) | 2007-10-09 |
TW200619212A (en) | 2006-06-16 |
CN101014580B (zh) | 2011-05-04 |
US20070265257A1 (en) | 2007-11-15 |
CA2579207A1 (en) | 2006-03-16 |
EP1801108A1 (en) | 2007-06-27 |
CN101014580A (zh) | 2007-08-08 |
JPWO2006028284A1 (ja) | 2008-05-08 |
PT1801108E (pt) | 2012-12-03 |
TWI367209B (US06903085-20050607-C00131.png) | 2012-07-01 |
US7935700B2 (en) | 2011-05-03 |
CA2579207C (en) | 2011-10-18 |
JP4970946B2 (ja) | 2012-07-11 |
EP1801108B9 (en) | 2013-11-20 |
DK1801108T3 (da) | 2013-02-18 |
PL1801108T3 (pl) | 2013-04-30 |
EP1801108A4 (en) | 2010-10-13 |
IN2014CN03493A (US06903085-20050607-C00131.png) | 2015-07-03 |
KR101011848B1 (ko) | 2011-02-01 |
EP1801108B1 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006028284A1 (ja) | モルホリン化合物 | |
AU2002223034B2 (en) | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | |
AU773047B2 (en) | Triazole compounds with dopamine-D3-receptor affinity | |
JP5344564B2 (ja) | スルホキシイミン置換ピリミジン、それらの調製及び医薬としての使用 | |
US7968571B2 (en) | 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease | |
CA3075751A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
JP2017522346A (ja) | ブロモドメインに対して活性な化合物 | |
CA2565211A1 (en) | Amino-tetrazoles analogues and methods of use | |
JP2002528499A (ja) | Impdh酵素のインヒビターであるアミノ核誘導化合物 | |
PT1910348T (pt) | Compostos de benzotiazol e azabenzotiazol úteis como inibidores de quinases | |
BR122017002951A2 (pt) | amidas heterocíclicas como inibidores de quinases | |
CA2693182A1 (en) | Pyrimidine compounds, methods of synthesis thereof, and use thereof in the treatment of raf kinase-mediated disorders | |
CA2694284A1 (en) | Heterocyclic compounds useful as raf kinase inhibitors | |
WO2008057775A2 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
WO2009026701A1 (en) | Sirtuin inhibitors | |
EA026361B1 (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
JP6559699B2 (ja) | 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用 | |
WO2005103012A1 (ja) | ヒドラジノ複素環ニトリル化合物およびその用途 | |
TW200932221A (en) | Imidazole carbonyl compounds | |
MXPA05004305A (es) | Compuestos de triazol para el tratamiento de dismenorrea. | |
AU2014200030A1 (en) | Pyrimidine Derivatives Useful as Raf Kinase Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2579207 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006535186 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580030137.0 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005783689 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1421/CHENP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077007863 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11662228 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005783689 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11662228 Country of ref document: US |